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Das Nierenzellkarzinom ist der am häufigsten in den Nieren vorkommende Tumor. Er macht 
bis zu 3% aller malignen Erkrankungen bei Erwachsenen aus. Die Zahl der 
Nierenzellkarzinompatienten steigt jährlich. Bisher gibt es keine international standardisierte 
Therapie für das metastasierende Nierenzellkarzinom und die vollständige Entfernung der 
betroffenen Niere ist zur Zeit die einzige Behandlungsmöglichkeit. Das Nierenzellkarzinom 
ist sehr resistent gegen Bestrahlung und Chemotherapie, zeigt aber in manchen 
Untersuchungen eine spontane Regression, die auf Immunogenität des Tumors schließen 
lässt. Die Identifikation von nierenzellkarzinomassoziierten immunogenen Molekülen ist 
daher wichtig, um 1.) die grundlegenden Mechanismen der Immunogenität des 
Nierenzellkarzinoms zu verstehen, 2.) für mögliche neue Ansätze in Diagnose, Prognose und 
Therapie. 
 
In dieser Arbeit wurden drei Techniken eingesetzt, um nierenzellkarzinomassoziierte Gene 
und Antigene zu erkennen: 1) Suppression substractive hybridization (SSH), 2) Serological 
analysis of recombinant cDNA expression libraries (SEREX), 3) Serum antibody detection 
array (SADA). 
 
Durch die SSH-Methode konnte gezeigt werden, dass zwei Gene (BACE2 und SUPT5H) in 
50% der getesteten Nierenzellkarzinompatienten stark überexprimiert sind. In 35 
Nierenzellkarzinompatienten wurde das Expressionsmuster von neun anderen durch SSH 
identifizierten Genen (Semaphorin G (SemG), lysyl oxidase (LO), autotaxin (ATX), 
angiopoeitin-related protein (ARP2), ceruloplasmin (CP), vascular endothelial growth factor 
(VEGF), C1 respiratory complex (C1-RC), cyclin D1 und insulin-like growth factor binding 
protein-3 (IGFBP3) untersucht. Einige dieser Gene sind in 80-90% der untersuchten 
Nierenzellkarzinome überexprimiert, ein Hinweis auf die Wichtigkeit dieser Gene in der 
Tumorprogression. Hochregulierung von C1-RC, SUPT5H, VEGF, ARP2, ATX, LO und 
SemG korreliert mit der histologischen Untergruppe des „clear-cell“-Nierenzellkarzinoms, 
während BACE2 vermehrt im „mixed“- und „oxyphil“-Typ überexprimiert wird. 
 
Der Differenzierungsgrad des Tumors steht in keinem Zusammenhang zur Überexpression 
der Gene, nur Hochregulierung von ATX und LO korreliert mit erhöhter Tumorprogression. 
 
Die SEREX-Methode wurde angewandt, um Bibliotheken von Lambda-Phagen zu testen, die 
hergestellt wurden, aus 1) Nierenzellkarzinomgewebe, 2) Nierenzellkarzinom-Zelllinie 
(KTCTL-28) behandelt mit 5-aza-2´deoxycytodine, 3) Gewebe männlicher Keimzellen 
 
Aus 4,5x 106 gestesteten Plaques resultierten 234 positive Klone, die 74 verschiedenen 
Genprodukten entsprechen. Anhand von Sequenzanalysen und Literaturrecherche konnten 
diese Antigene in folgende Kategorien eingeteilt werden: Cancer-Testis-Antigene, Antigene 
mit eingeschränkter Expression, Antigene mit heraufregulierter Expression, Antigene mit 
Chromosomentranslokationen, normale Autoantigene und unbekannte Antigene. 
 
Seroreaktivität einige dieser Antigene war beschränkt auf Nierenzellkarzinompatienten. Dies 
kann als diagnostischer Marker oder potentiell in der Therapie eingesetzt werden. 
 
Mit der SADA-Methode wurde Seroreaktivität der Nierenzellkarzinompatienten-Seren gegen 
44 bekannte Antigene untersucht. 8 Antigene reagierten nur mit Seren von 
Nierenzellkarzinompatienten und nicht mit Seren von Personen der gesunden Kontrollgruppe. 
Seroreaktivität gegen drei der Antigene (Par-3, se57-1 und HEXIM1) war in einem 
wesentlichen Anteil der Patienten (11-23%) zu verzeichnen und könnte als diagnostischer 
Marker Verwendung finden. 
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Renal cell carcinoma accounts for up to 3% of all adult malignancies and is the most common 
neoplasm in the adult kidney. The incidence of RCC is increasing yearly. There is no 
internationally standardized treament for metastatic RCC and the only curative option for 
localized RCC is radical nephrectomy. RCC is known to be highly chemoresistant and 
radioresistant. However, it is thought to be immunogenic, as there are frequent reports of 
spontaneous regression. Identification of RCC associated immunogenic molecules is therefore 
a priority in order to 1) understand the underlying mechanisms of immunogenicity of RCC 
and 2) to identify potential diagnostic, prognostic and therapeutic targets. 
 
In this thesis, three techniques have been used to identify RCC associated genes and antigens: 
1) Suppression subtractive hybridization (SSH) 2) Serological identification of antigens by 
recombinant expression cloning (SEREX) and 3) Serum antibody detection array (SADA) 
analysis.  
 
Through SSH, two genes (BACE2 and SUPT5H) could be shown to be highly upregulated in 
the tumors of approximately 50% (for both) of all RCC patients tested. The expression profile 
of 9 other genes : semaphorin G (SemG), lysyl oxidase (LO), autotaxin (ATX), angiopoeitin-
related protein (ARP2), ceruloplasmin (CP), vascular endothelial growth factor (VEGF), C1 
respiratory complex (C1-RC), cyclin D1, and insulin-like growth factor-binding protein-3 
(IGFBP3), previously identified by SSH was also examined in 35 RCC patients. 
Overexpression for some of these genes was found in 80-90% of RCC thus indicating the 
importance of these genes in tumor progression. Upregulation of C1-RC, SUPT5H, VEGF, 
ARP2, ATX, LO and SemG appear to correlate with the clear cell RCC histological subtype 
whereas upregulation of BACE2 has been found more in the mixed and oxyphil type. There 
was no correlation of gene overexpression with tumor grading and only ATX and LO showed 
a correlation with tumor progression. 
 
The SEREX method has been used here to screen three l-phage libraries derived from 1) an 
RCC tumor, 2) an RCC cell line (KTCTL-28) treated with 5-aza-2’-deoxycytidine and 3) 
testis tissue. Approximately 4.5 x 106 phage plaques were screened resulting in 234 positive 
clones. This corresponded to 74 different gene products. Through sequence analysis and 
examination of the literature, these antigens could be grouped into the following categories: 
Cancer/ Testis, Restricted expression, Upregulated antigens, Translocation antigens, Normal/ 
autoantigens and Unknown antigens. Seroreactivity to some of these antigens was restricted to 
RCC patients and may serve as diagnostic markers or potential therapeutic targets. 
 
Finally, seroreactivity against a panel of 44 antigens was examined with RCC sera via the 
SADA method. In total, 14 antigens were found to react with RCC sera. Of these, 8 were 
reactive only in RCC patients and not in healthy controls. Seroreactivity to 3 of these antigens 
(Par-3, se57-1 and HEXIM1) was found in a significant proportion of RCC patients (11-23%) 
and may be suitable diagnostic markers. 
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1. Introduction 
 
 
1.1 Renal Cell Carcinoma 
 
 
1.1.1 Etiology 
 
Renal cell carcinoma (RCC) accounts for approximately 3% of all cancer related deaths. In 
Germany RCC is the eighth most common cause of male cancer. In the United States RCC 
accounted for over 31000 new cases and led to approximately 12000 deaths in 2001. The high 
mortality rate is due to the fact that over one third of RCC cases present with metastatic 
disease and 30% of those treated for localized disease eventually relapse. The causes of RCC 
have not been investigated as frequently as lung, breast and colon cancers. However, a 
number of risk factors have been identified. 
 
 
1.1.2 Risk factors  
 
Smoking. One-third of all cases of renal cancer are attributed to cigarette smoking (Motzer et 
al. 1996). Increased risks have been found in long-term or heavy smokers. As with other 
cancers, the risk declines within a few years after the cessation of smoking (McLaughlin et al. 
1995). 
 
Nutrition. Diet has been shown to be a major factor in the causes and prevention of kidney 
cancer. The influence of diet can best be appreciated by comparing international rates of 
kidney cancer. Asian populations have a 5-8 fold lower incidence than Western countries. 
Fried meats, especially poultry seem to be associated with an increased risk of RCC (Wolk et 
al 1996) while the consumption of fruit and cruciferous vegetables has been shown to have a 
protective effect (Wolk et al 1996, Yuan et al 1998). 
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Obesity. High body weight or body mass index has been shown to be a risk factor for renal 
cell carcinoma, particularly in females (Motzer et al. 1996). This may be due to the fact that 
obesity increases estrogen production which has been shown to promote kidney tumors in 
hamsters ( Liehr 1997). 
 
Drugs and alcohol. The use of antihypertensive drugs are considered a risk factor for RCC 
(Motzer et al. 1996; McLaughlin et al. 1995). However, it was reported that the independent 
effects of treatment for hypertension could not be distinguished from the effects of 
hypertension itself. Alcohol itself has not been demonstrated to be a risk factor for RCC 
despite the correlation of kidney cancer mortality rates with per capita intake of alcohol 
(Breslow et al 1974). 
 
Occupation. A number of studies have demonstrated exposure to asbestos and cadmium as 
risk factors for RCC (Mandel et al. 1995, Pesch et al 2000). Increased risks have also been 
linked to exposures in coke production, the iron and steel industry, chemical cleaning 
solvents, engine fuels, and other petroleum products.  
 
Hormonal factors. The IRCC study (Lindblad et al 1995) has demonstrated that risk of kidney 
cancer increases linearly with two or more births, compared to one birth. Unrelated factors 
were age at menopause and estrogen replacement therapy. An increased risk was observed for 
women having had both a hysterectomy and an oophorectomy. Use of oral contraceptives in 
non-smoking women reduced the risk of renal-cell cancer. 
 
Genetic factors. There are four major hereditary types of renal cell carcinoma. The most 
studied being von Hippel Lindau disease (VHL). VHL is caused by mutations in the VHL 
gene located on chromosome 3p (Latif et al 1993). Less common is hereditary clear cell renal 
cell carcinoma (HCRC). This is caused by translocations of the short arm of chromosome 3p 
(Cohen et al 1979). The third and fourth hereditary forms are hereditary papillary renal 
carcinoma (HPRC), characterized by germline mutations in the met gene (Schmidt et al 1997), 
and hereditary renal oncocytoma (HRO) which has only relatively recently been described 
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(Weirich et al 1998). All of the hereditary forms appear to occur at a younger age than 
sporadic renal cancers (Linehan et al 1995) and are usually bilateral and multifocal. 
 
 
1.1.3 Prognostic factors  
 
Histology. There are four major histological classifications for RCC (Table 1). Clear cell RCC 
are the most common accounting for 70-80% of all RCC. They arise in the proximal tubules 
and on gross inspection have a yellowish appearance due to their high lipid content (Storkel et 
al 1997). Papillary RCC are the second most common at 10-15%. The architecture of these 
tumors may be papillary, tubular, tubulo-papillary, or solid (Zambrano et al 1999). These are 
also thought to arise from the proximal renal tubular epithelium. Chromophobe tumors 
account for 5% of RCC and arise from the intercalated cells of the collecting ducts. 
Genetically, chromophobe tumors are characterized by monosomy of multiple chromosomes, 
including, 1, 2, 6 and 10 (Pantuck et al 2001). Collecting duct carcinomas is a very aggressive 
form but are rare and account for less than 1% of RCC. Finally, unclassified RCC 
encompasses a heterogeneous group of tumors that includes tumors with extensive necrosis 
and minimal viable classifiable tumor, mucin-producing tumors, and tumors with sarcomatoid 
change in which the epithelial elements cannot be classified (Amin et al 2002). 
 
Tumor stage. Tumor stage is considered one of the most important prognosticators for RCC. 
There are two forms of staging in current use, the Robson classification and the Tumor-Node-
Metastasis (TNM) system (Table 2). According to the TNM system, the T value reflects the 
size of the tumor, N reflects the number of metastasis to lymph nodes, and M reflects the 
number of distant metastasis. From these three categories, RCC can be divided into four 
stages (Table 2). 
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Histological type Occurrence      
(% of RCC) 
Origin Variants 
Clear cell 70-80 Proximal tubules A) Sporadic. Up to 60% with VHL 
mutation 
B) Hereditary. Up to 40% with VHL 
disease will develop clear cell 
RCC 
Papillary 10-15 Proximal tubules A) Type 1-basophilic cytoplasm 
B) Type 2- eosinophilic cytoplasm 
Chromophobe 3-5 Intercelated cells 
of collecting 
ducts 
A) Typical/Classical 
B) Eosinophilic/Granular 
Collecting duct < 1 Medulla of 
collecting ducts 
Usually seen in African Americans with 
sickle cell disease or trait 
Unclassified 
RCC 
  For any tumors not fitting the above 
histological types 
Table 1. Summary of histological classification of RCC 
 
T1a 
T1b 
Tumor less than or equal to 4cm and limited to the kidney 
Tumor greater than 4cm but less than 7 cm and limited to the kidney 
T2 Tumor greater than 7cm and limited to the kidney 
T3 
 
T3a 
Tumor extends into major veins, or invades adrenal gland or perinephric tissues, but 
confined to Gerota’s fascia 
Tumor invades adrenal gland or perinephric tissues, but confined to Gerota’s fascia 
T3b Tumor extends into renal vein or inferior vena cava below the level of diaphragm 
T3c Tumor extends into renal vein or inferior vena cava above the level of diaphragm 
T4 Tumor extends to Gerota’s fascia  
N0 No regional lymph node metastasis 
N1 Metastasis to a single regional lymph node 
N2 Metastasis to more than one regional lymph node 
M0 No evidence of distant metastasis 
M1 Distant metastasis 
 
 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T1, T2 
T3 
N1 
N0,N1 
M0 
M0 
Stage IV T4 
Any T 
Any T 
N0,N1 
N2 
Any N 
M0 
M0 
M1 
Table 2. TNM staging  
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Tumor grade. Tumor grade is the second most important prognosticator for RCC. The grade 
reflects the nuclear morphology. The current system in use is the Fuhrman system (Table 3). 
Unfortunately, controversy still exists concerning the inter-observer reproducibility of grading 
and the 1997 UICC/AJCC conference was unable to improve the system. 
 
 
Grade Nuclei Characteristics Size 
1 Round and uniform contour 10 mm nuclei 
2 Irregular contour 15 mm nuclei 
3 Very irregular contour 20 mm uclei 
4 Bizzare and irregular At least 20mm 
Table 3. The Fuhrman grading system 
 
 
Molecular markers. Molecular markers that have been shown to have some prognostic value 
in RCC include DNA ploidy (Ljungberg et al 1986), cytogenetic changes such as deletions or 
translocations of chromosome 3p (Elfving et al  1997), increased levels of the proliferation 
markers proliferating cell nuclear antigen (PCNA) and Ki-67 (Onda 1999), and increased 
levels of apoptosis related molecules such as bcl-2 (Vasavada et al 1998). 
 
 
1.1.4 Treatment 
 
Surgical. Radical nephrectomy is the current established form of treatment for localized 
unilateral RCC. However recent studies have shown that nephron-sparing surgery (NSS) can 
be equally as beneficial for patients whose tumors are localized and no bigger than 4 cm. It 
has also been shown that NSS provides a long-term renal functional advantage over radical 
nephrectomy (Steinbach et al 1992). In the case of metastatic RCC, radical nephrectomy is 
only used in a palliative manner.  
 
Chemotherapy and Radiotherapy. RCC has proven to be highly resistant to both 
chemotherapy and radiotherapy. The only cytotoxic agents that have proven to be someway 
effective are 5-fluorouracil (5-FU) and floxuridine. Both of these appear to be more active 
when used in conjunction with immunomodulators such as interleukinn-2 (IL-2) (Yagoda et al 
1995) 
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Immunomodulators. Objective responses of 15% has lead to the approval by the USA Food 
and Drug Administration (FDA) of IL-2 for the treatment of metastatic RCC (Fyfe G et al 
1995). However the high-dose bolus treatment is itself highly toxic with a treatment related 
mortality of up to 4%. Recent clinical trials have tried to reduce the toxicity via continuous 
high-dose intravenous infusion or subcutaneous infusion. A clear decrease in toxicity as well 
as comparable response rates were found (Yang et al 1997, Heinzer et al 2001). However, no 
randomized study of sufficient size has been published to date. The use of IFNa has been 
extensively examined as a treatment option for RCC by itself and in combination with other 
chemo- and immunotherapeutic agents. In two large trials, IFNa alone was reported to have a 
small but significant effect (Ritchie et al 1998, Pyrhonen et al 1996). However, to date, there 
has been no sufficiently large randomized Phase III trial showing a survival benefit for 
combination therapy compared to single-agent interferon. 
 
Cellular therapy. Cell based therapies include the use of lymphokine activated killer (LAK) 
cells, tumor infiltrating lymphocytes (TIL), allogenic stem cells (allo-SCT) and dendritic 
cells. Despite promising in vitro results with LAK and TILs, randomized trials have shown no 
clinical benefit for these two approaches (Hoffman et al 2000). In two studies allo-SCT 
treatment after non-myeloablative chemotherapy has shown objective response rates of up to 
53% (Childs et al 2000, Rini et al 2002). However, substantial toxicity due to graft-versus-
host disease was encountered. This high toxicity may be reduced by first depleting the graft of 
T-cells and is currently under investigation. Studies involving dendritic cells are only at a 
relatively early stage and trials so far have only been able to show the safety and feasability of 
DC-based vaccines. 
 
Monoclonal antibody therapy. The G250 antigen, also known as carbonic anhydrase 9, is 
expressed on more than 75% of primary and metastatic RCC (Oosterwijk et al 1986) but not 
on normal kidney tissue. This makes it a promising candidate for directed immunotherapy. 
Clinical trials using Iodine-131 labelled G250 antibodies have thus far demonstrated its 
specific antitumor effect (Divgi et al 1998). 
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1.2 Tumor immunology 
 
 
1.2.1 Tumor Antigens 
 
 
Rejection of tumors can only occur if the immune system recognizes the tumor as foreign. 
This recognition is mediated through antigens on the surface of the tumor. Different types of 
tumor antigen specificity exist (Table 4). 
 
 
Antigen Type Example Reference 
Cancer/Testis MAGE-A, RAGE, NY-
ESO-1 
van der Bruggen et al 1991, 
Gaugler et al 1996, Jäger et al 
1998 
Differentiation Tyrosinase,  Brichard et al 1993,  
Mutation (point or frameshift) p53, CDX2 Scanlan et al 1998, Ishikawa 
et al 2003 
Translocation 
 
DEK-CAN, BCR-ABL 
 
Ohminami et al 1999, Berke 
et al 2000 
Splice Variant cTAGE Usener et al 2003 
Post-translational modification Cytochrome-c Mamula et al 1999 
Post-translational protein splicing Fibroblast growth factor 
5 
Hanada et al 2004 
Gene amplification/overexpression Her-2/neu Hynes et al 1994 
Cancer related autoantigen CEBP Tureci Ö et al 1999 
Cancer independent autoantigen 
Viral 
U1-snRNP 
HERV-K10 
Chen et al 1997 
Tureci et al 1997 
Table 4. Classification of tumor antigens 
 
 
Cancer/Testis antigens As the name suggests, Cancer/Testis antigens (CT-antigens) are 
expressed only in the testis and in various tumor types. Many of the CT-antigens are shared 
between different tumor types. For example, the MAGE-A genes have been found in 
malignant melanomas and carcinomas of the lung, head and neck as well as urinary bladder 
(Jungbluth et al 2000). The coincident expression of CT-antigens in cancer and testis is 
thought to be due to hypomethylation of CpG islands which is constitutive in testis but also 
occurs in tumors (De Smet et al 1996, Erickson et al 1993). Demethylation of CpG islands 
leads to the expression of genes that would normally be silent. With few exceptions (SCP-1 
Kondoh et al 1997), most CT-antigens are localized to the X chromosome. Many of the CT-
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antigens belong to multigene families. The MAGE A family contains 15 family members (van 
der Bruggen et al 1991) and the closely related MAGE-B family has 17 members (Muscatelli 
et al 1995). The natural function of most, again with the exception of SCP-1 (involved in the 
correct pairing of homologous chromosomes during meiosis, Meuwissen et al 1997), of the 
CT-antigens is unknown. However, they remain the prime candidates for immunotherapeutic 
strategies against cancer due to their restricted expression and the immune-privileged nature 
of the testis. Currently there are several clincal trials involving MAGE peptides for the 
treatment of malignant melanoma. In one trial with MAGE 3 peptides in HLA A1 patients, 
seven of 25 patients showed significant tumor regression, including three cases of complete 
remission (Marchand et al 1999). 
 
Differentiation antigens Differentiation antigens are antigens derived from genes that show a 
lineage-specific expression in tumors and in the normal cells of the same origin. The 
tyrosinase gene is one example. It is expressed normally by melanocytes and is involved in 
the production of melanin. However, it has also been shown to induce both cellular and 
humoral immune responses in malignant melanoma patients (Coulie et al 1994, Sahin et al 
1995). 
 
Mutated antigens Mutations can arise from point mutations resulting in the change of a single 
amino acid or frameshifting where the open reading frame of the protein is shifted. Mutated 
antigens are generally unique and restricted to the patient in which the mutation arises. 
Therefore these antigens are unsuitable for immunotherapy purposes. 
 
Translocation antigens Translocation between chromosomes is a common occurrence in 
neoplastic cells. New fusion proteins can result from these translocations and these are very 
often immunogenic. The BCR/ABL fusion protein is a result of a translocation between 
chromosomes 9 and 22. This translocation is particularly associated with Chronic 
Myelogenous Leukemia (CML). Recently, a clinical trial using a specific BCR/ABL inhibitor 
(Imatinib mesylate) has shown complete hematologic response in 98% of the patients treated 
and a complete cytogenetic response in 72% (Duffy 2003). Cancer related fusion proteins 
represent ideal targets for immunotherapy due to their expression solely on the tumor. 
 
Splice variants Splice variants are also likely to be immunogenic as has been shown for the 
Hodgkin’s disease associated antigen restin ( Sahin et al 1995). 
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Post translational modifications Antigens resulting from aberrant post translational 
modification of proteins are also likely to be highly immunogenic. Post translational 
modifications include acetylation, glycosylation and isoaspartylation. For the latter case it has 
been demonstrated that isoaspartylation of cytochrome c peptides results in the induction of 
strong B and T cell autoimmune responses in mice (Mamula et al 1999). However the 
identification of such antigens is difficult due to the fact that antibodies tend to be cross 
reactive with both the wild type and modified forms (Mamula et al 1999). 
 
Post-translational protein splicing Post translational protein splicing has only been recently 
described (Hanada et al 2004). It represents a completely new class of antigen. It also has 
major implications for the proteome and immunome alike. Hanada and colleagues found that 
a CTL directed against Fibroblast growth factor-5 (FGF-5) was specific for a nonapeptide that 
could only have been generated by splicing together two parts of the protein that are normally 
60 amino acids apart. The question remains as to how often this occurs and to what purpose. 
 
Gene amplification/overexpression Overexpression of gene products through gene 
amplification, increased induction or stability of mRNA or the protein product can result in 
the induction of an immune response due to the overriding of critical thresholds which are 
necessary for the maintenance of tolerance. Overexpression of genes is a common event in 
cancer and often these genes are involved in some aspect of tumor progression such as 
apoptosis inhibition, proliferation, adhesion or migration. Some examples of overexpressed 
genes acting as antigens include Aldolase A in lung carcinoma (Güre et al 1998), elF-4g in 
small cell lung carcinoma (Brass et al 1997), carbonic anhydrase XII in renal cell carcinoma 
(Türeci et al 1998) and Her-2/neu in breast carcinoma (Disis et al 1994). The recently 
developed trastuzumab is a humanized monoclonal antibody against Her-2/neu. Clinical trials 
with trastuzumab alone or in combination with other chemotherapeutic drugs have shown 
substantial benefits for patients with metastatic breast cancer (Vogel et al 2003). 
 
Cancer related autoantigen Cancer related autoantigens are genes that are ubiquitously 
expressed and at similar levels in both normal and neoplastic tissues. However, antibodies 
against these genes are only generated in cancer patients. The mechanism involved here is 
unclear but may be due to changes in antigen presentation and/or processing in tumor cells.  
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Cancer independent autoantigen The presence of antibodies against cancer independent 
autoantigens is not related to neoplastic disease and are found in equal proportions of healthy 
individuals and cancer patients. The role of these autoantigens in the immune system is 
unclear. One suggestion is that these autoantigens maintain and regulate immunological 
homeostasis via CD4+CD25+ regulatory T cells (Nishikawa et al 2003). 
 
Viral antigens Viral antigens are ideal candidates for immunotherapy or preventative 
vaccination. One example identified so far is that of HERV-K10 in renal cell carcinoma 
(Türeci et al 1997). 
 
 
 
1.2.2 Methods for the identification of tumor antigens  
 
 
The repertoire of tumor antigens recognized by the immune system is referred to as the cancer 
immunome. The immunome comprises antigens defined by T cell epitope cloning, MHC 
peptide elution and serological methods such as SEREX (serological analysis of recombinant 
cDNA expression libraries) or SERPA (serological proteome analysis). Other techniques 
which may sometimes identify antigens include suppression subtractive hybridization (SSH), 
differential display RT-PCR (DD-RTPCR) and DNA microarray hybridization. 
 
T cell epitope cloning T cell epitope cloning was pioneered by the group of Thierry Boon and 
led to the identification of the first human tumor antigen in 1991 (van der Bruggen et al 
1991). Since then many more antigens recognized by cytotoxic T lymphotes (CTLs) have 
been identified. A database compiling all CTL identified antigens to date has been established 
and is located on the internet at www.cancerimmunity.org/peptidedatabase/Tcellepitopes. In 
this method a cDNA library is generated from a tumor and transfected into COS-7 or 293 cell 
line cotransfected with the MHC of the original tumor. The cDNA encoding the tumor antigen 
is then determined by the response of autologous CTLs against the transfected COS-7 or 293 
cells. T cell epitopes can then be identified by generating synthetic peptides from the 
identified gene that fit the MHC of the original tumor and looking for responses of the CTLs 
to peptide loaded APCs. Some drawbacks to this method include the difficulty in establishing 
autologous CTLs in non melonoma tumors and the requirement for identifying the MHC of 
the patient in question. 
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MHC peptide elution This is a more direct approach to the identification of MHC restricted 
epitopes. It involves the acid elution of peptide-MHC complexes from the surface of tumor 
cells and subsequent seperation by reverse phase high performance liquid chromatography 
(RP-HPLC). Each fraction is then sequenced by mass spectrometry. Peptides identified by 
this manner still have to be tested for their ability to stimulate CTLs. One advantage however, 
is the fact that peptides identified are the naturally processed forms. On the other hand it is a 
highly complex methodology. The SYFPEITHI database of MHC ligands and peptide motifs 
can be found at www.syfpeithi.bmi-heidelberg.com 
 
Serological techniques Serological techniques aim to identify the repertoire of circulating 
antibodies in cancer patients. As the production of antibodies by B cells is thought to require 
T cell help, this reflects the CD4+ helper T cell repertoire. The SEREX method is by far the 
most successful method to date for the identification of circulating antibodies. This method 
was developed by Ugur Sahin and colleagues (Sahin et al 1995) as an improvement on the 
original method of autologous typing. In the SEREX approach (Figure 1), a cDNA library is 
generated from a tissue or cell line of choice (normally fresh tumor tissue). The cDNA is then 
cloned unidirectionally into a l-phage vector. The resulting recombinant phages are then used 
to transfect Escherichia coli. Recombinant proteins, which are expressed during lytic 
infection of the bacteria, are transferred onto a nitrocellulose membrane which is then 
incubated with patient sera. Antibodies in the sera of the patient reacting with the recombinant 
proteins can then be detected with an enzyme-conjugated secondary antibody specific for 
human IgG. Positive clones are then subcloned to monoclonality and then converted to 
plasmids via in vivo excision. The insert can then be sequenced to identify the gene 
responsible for the antibody response. To date there are 2593 identified sequences in the 
SEREX database (www2.licr.org/CancerImmunomeDB/) derived from 2169 clones. Many of 
the genes have been isolated repeatedly from the same and/or various tumor types, thus 
indicating their high immunogenicity in the human host. One of the main advantages of 
SEREX is that cDNA libraries can be prepared from fresh tissue, thus obviating the need to 
culture tumor cells which are prone to loss of or neoexpression of antigens resulting in 
artifacts. Another advantage is that by using highly diluted patient sera (1:100 to 1:1000), 
only high-titer IgG antibodies are detected which reflects a strong immune response by the 
host. Some disadvantages of SEREX are that it cannot detect glycosylated epitopes or 
conformational epitopes. A development of SEREX is the SADA (serum antibody detection 
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array) method (Figure 2). This allows the screening of multiple previously identified antigens 
by multiple sera in one go. This method is used to define the seroreactivity of a group of 
patients against defined antigens. One method which addresses some of the shortcomings of 
SEREX is the SERPA (serological proteome analysis) approach (Klade et al 2001). In this 
method, protein lysates from normal tissue and tumor tissue are seperated by 2D gel 
electrophoresis. Proteins are then transferred to a membrane and screened with patient sera as 
in SEREX. Comparison of seroreactivity against normal tissue and tumor proteins identifies 
spots which are then sequenced by mass spectrometry. The advantage of SERPA over 
SEREX is that proteins are in their naturally processed forms with all the proper post-
translational modifications. However the sensitivity is much less as compared to SEREX. 
 
 
Molecular biological techniques Molecular biological techniques such as SSH, DD-RTPCR 
and hybridization of cDNA microarrays are very efficient at identifying differentially 
expressed genes. However the majority of genes identified by these techniques are not 
immunogens. In the SSH method one population of cDNA (driver e.g. normal kidney) is 
subtracted from a second population (tester e.g. renal cell carcinoma) via hybridization and 
subsequent PCR amplification from adaptors linked to the tester cDNA. Amplified products 
are then transformed into bacteria and subsequently sequenced. All identified clones have 
then to be checked for expression levels by Northern blotting or RT-PCR. In the DD-RTPCR 
method RT-PCR using a set of oligonucleotide primers is performed on two populations of 
mRNA and then compared on a DNA sequencing gel. A banding pattern is generated for each 
population and differentially expressed bands can be excised, gel-eluted, cloned into a vector 
and subsequently sequenced. Both up and down regulated genes can be identified by this 
method. Two major drawbacks of this method are the high incidence of false positives and the 
fact that there can be more than one cDNA species present within one amplified band. The 
hybridization of cDNA microarrays is a highly powerful technique for the identification of 
differentially expressed genes. Many thousands of cDNAs can be compared in one 
experiment. The only drawbacks being the high cost and the fact that unknown genes are not 
represented. 
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                                                       Figure 2. The SADA method 
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1.2.3 Renal cell carcinoma antigens  
 
 
In comparison with other cancers such as melanoma, relatively few antigens have been 
identified to date in RCC. Table 5 lists the known RCC associated antigens to date. One of the 
RCC associated antigens identified by the T cell epitope cloning method is RAGE-1 (Gaugler 
et al 1996). RAGE-1 is expressed normally only in the retina. The frequency of its expression 
in RCC ranges from 2% to 36% depending on which study you read (Gaugler et al 1996, 
Neumann et al 1998, Oehlrich 2004, respectively). The study by Neumann et al also examined 
the expression of numerous other tumor associated antigens. By RT-PCR they could detect 
expression of PRAME (preferentially expressed antigen in melanoma) in 40% of RCC 
samples and gp75 in 11% whereas no expression could be found for MAGE-1, NY-ESO-1, 
tyrosinase, Melan-A/MART-1, gp100, beta-catenin, or MUM-1. Van den Eynde et al (1999) 
have identified another CTL epitope which they named RU2AS. The epitope is derived from 
the protein product of the antisense mRNA of RU2S. The antigen was found not to be tumor 
specific but to be a self-antigen with restricted tissue distribution. 
 
The serological methods have had a little more success. Sahin et al performed the first 
SEREX on RCC in 1995. They identified one gene (carbonic anhydrase XII) which was found 
to be overexpressed in 10% of RCC. A subsequent study by Türeci et al in 1998 identified a 
new member of the cancer/testis antigen family, namely SCP-1(synaptonemal complex 
protein 1). It was found to be expressed in 3 of 36 RCC samples aswell as 40% of gliomas 
and 27% of breast carcinoma samples. Scanlan et al (1999) analyzed four additional cases of 
RCC and found 169 clones representing 65 different gene products. Of these, 36 were coded 
for by known genes and 29 were novel gene products. All the genes identified were found to 
be expressed in a range of normal tissues. With regard to the immunogenicity of these clones, 
12 of the antigens were found to have cancer related seroreactivity i.e. antibodies were 
detected in 5-25% of patients but not in healthy controls. Koreleva et al (2002) used SEREX 
on two RCC specimens and identified a total of 96 clones corresponding to 66 different genes. 
Of these, 18 genes were of unknown function. Four of the genes were found to have a cancer 
related seroreactivity. However very little is known about these clones to date. The two 
proteomic studies of RCC (Klade et al 2001, Unwin et al 2003) have identified 12 antigens 
reacting with sera from RCC patients. Interestingly carbonic anhydrase I (CA I) was 
identified in both studies. Two other carbonic anhydrase members, CA IX/G250  (Oosterwijk 
et al 1986) and CA XII (Türeci et al 1998), have previously been shown to be RCC-tumor 
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antigens. The G250 antigen had been identified through a mouse monoclonal antibody 
specific for RCC and not normal tissue or other tumor tissues. It is the most promising 
candidate so far for immunotherapy of RCC. 
 
 
Method of Identification Antigen Reference 
CTL epitope cloning RAGE-1 Gaugler et al 1996 
 iCE Ronsin et al 1999 
 HSP70-2M 
HLA-A2 R170 
RU1 
Gaudin et al 1999 
Brandle et al 1996 
Morel et al 2000 
 
SSH 
RU2 
MAGE-9 
Van den Eynde 1999 
Pitzer et al 1999 
SEREX SCP-1 Türeci et al 1998 
 NY-REN-9 Scanlan et al 1999 
 NY-REN-10 Scanlan et al 1999 
 NY-REN-19 Scanlan et al 1999 
 NY-REN-26 Scanlan et al 1999 
 MO-REN-46 Koroleva et al 2002 
 MO-REN-54 Koroleva et al 2002 
 MO-REN-103 Koroleva et al 2002 
 MO-REN-205 Koroleva et al 2002 
 CA XII Sahin et al 1995 
SERPA/SPEAR CA I Klade et al 2001, Unwin et al 
2003 
 SM22a Klade et al 2001 
 Thymidine Phosphorylase Unwin et al 2003 
Monoclonal antibodies MN/CA IX/G250 Oosterwijk et al 1986 
Table 5. RCC associated antigens 
 
 
1.2.4. Immunotherapy 
 
 
  1.2.4.1 Non specific Immunotherapy 
 
Non-specific immunotherapy aims to boost the body’s own immune system against cancer 
cells. In the normal course of a bacterial or viral infection, the body produces cytokines such 
as interleukin-2 (IL-2) or interferon-alpha (IFN-a) which then stimulate the growth and 
expansion of immune effector ells. However, non-specific immunotherapy is often toxic due 
to their lack of specificity. 
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Interleukin-2 Interleukin-2 (IL-2) is produced mainly by CD4+ T cells but also CD8+ T cells 
and large granular lymphocytes. It is thought to act by inducing the differentiation of 
lymphokine-activated killer (LAK) cells (Grimm et al 1992), maturation of antigen presenting 
cells (APCs) and enhanced ADCC (Eisenthal et al 1989). IL-2 can be given either alone or in 
combination with other treatment modalities. A high dose IL-2 bolus regimen has been 
approved by the FDA for the treatment of metastatic renal cell carcinoma. IL-2 has also been 
tested in combination with among others cyclophosphamide, interferon-a, histamine, and 
gp100 peptides. The combination of cyclophosphamide and low dose IL-2 used to treat 
melanoma patients was found to have an objective response rate of 25% (Mitchell et al 1988) 
as well as a lower toxicity than high dose IL-2 alone. Combinations of both IL-2 and IFN-a 
have been used to treat both RCC and melanoma with response rates up to 41% (Rosenberg et 
al 1989). However in a later comparison of IL-2 alone and IL-2 plus IFN-a, no difference in 
response rates could be observed (Marincola et al 1995). The combination of IL-2 plus 
histamine was found to benefit the subgroup of melanoma patients who had liver metastasis 
(Agarwala et al 2002). A 38% response rate was seen in a small group of melanoma patients 
receiving IL-2 in combination with a gp100 derived peptide (Rosenberg et al 1999). 
 
Interferons Interferons can be subdivided into three subgroups (-a, -b, -g). Their mechanisms 
of action are unclear but are thought to be stimulation of phagocytosis by macrophages, 
upregulation of MHC class I molecules and direct antitumor activities (Hancock et al 2000). 
To-date, the clinical relevance of IFN-b  and IFN-g for the treatment of metastatic RCC have 
not been proven. IFN-a, on the other hand has shown some benefit for patients. IFN-a may 
also be given alone or in combination with among others, vinblastine, 13-cis-retinoic acid, or 
IL-2. The combination of IFN-a and vinblastine was shown to be superior than vinblastine 
alone but not IFN-a alone (Pyrhonen et al 1999). In combination with 13-cis-retinoic acid 
(CRA) a higher response rate (12% versus 6%) was seen in those treated with the combination 
as compared to IFN-a alone (Motzer et al 2000). However no difference was seen in the 
median survival time. 
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1.2.4.2 Specific Immunotherapy  
 
The first step in rational design of cancer immunotherapy is the identification of a suitable 
antigen. The more antigens known for a particular cancer the better. Targeting of a single 
antigen may lead to tumor escape by selection of antigen loss variants. Therefore, the aim 
should be to immunize not only with one or two but with a number of different antigens 
simultaneously. However, the quality of the antigen with regard to tumor rejection is also 
important. The potency of a tumor rejection antigen depends not only on the strength of 
immune response induced but also the vaccination protocol used. Weak tumor antigens can 
record as strong rejection antigens when used in protocols that favour the induction of CTL 
responses plus Th-1 CD4+ T cell responses. Avidity and frequency of cognate T cells to a 
particular antigen are also important parameters. Several studies have shown that whereas 
low-avidity CTL can be readily detected by standard immunological assays, only high-avidity 
CTL exert biological function in vivo (Speiser et al 1992, Zeh et al 1999). A high frequency 
of responding T cells would conceivably be able to offset low avidity and thus result in an 
effective antitumor immune response. It is thought that the best tumor rejection antigens are 
those that are either patient-specific, tumor-specific or highly restricted shared antigens (such 
as the CT antigens) as these antigens are more likely to have been previously ignored by the 
immune system.  However, there is a case for non-mutated self antigens when used in the 
correct context. Nishikawa et al (2001) have shown that combined vaccination of mice with a 
known tumor rejection antigen plus a non-mutated self antigen results in increased 
antitumoral activity as compared to vaccination with the tumor rejection antigen alone. Once 
a tumor rejection antigen has been identified and selected, the next question is what strategy 
to use to elicit an effective antitumor response. There are a number of different strategies such 
as loading of denritic cells (DCs) with peptides, lentiviral transduction of DCs, monoclonal 
antibodies, and gene therapy.   
 
Dendritic cells Dendritic cells (DCs) have been shown to be the most potent antigen 
presenting cells of the immune system (Steinman 1991). DCs are uniquely able to prime both 
naïve CD4 or CD8 T cell responses making them central players in the activation of both 
cellular and humoral immune responses (see Figure 3). DCs also interact with natural killer 
cells (NK cells)(Fernandez et al 1999) and react to proinflammatory  factors (Luft et al 2002), 
thus providing a link between the adaptive and innate immune systems. 
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Figure 3. Central role of Antigen presenting cells in both humoral and cellular responses 
(Bleumer et al 2003). 
 
 
DCs can be isolated from CD34+ progenitor cells (Bernhard et al 1995) or from peripheral 
blood following attachment to plastic and maturation with cytokines such as GM-CSF, IFN-g 
and IL-4 (Xu et al 1995). 
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All clinical trials involving DCs revolve around the loading of DCs with the antigen of 
interest followed by in vivo or ex vivo expansion of reactive CD4+ or CD8+ T cells. Antigen 
can be loaded onto DCs by a variety of techniques. Peptides, designed to fit in the appropriate 
MHC molecule, can be pulsed directly onto DCs. Whole proteins can be given to immature 
DCs which then process the protein and present peptide products on the MHC. DCs can also 
be transfected with tumor RNA (Boczowski et al 2000) or transduced with lentivirus 
containing the gene of interest (Rouas et al 2002).  
 
Despite promising results in animal trials results from completed human DC trials have thus 
far only been able to demonstrate its safety. Conclusions about the efficacy and 
immunogenicity of DC vaccination have been hampered by the small scale of trials so far and 
by variables such as preparation of DCs, vaccine schedule and monitoring of the immune 
response. Efforts to standardize these procedures should give results that can be compared 
with other immunotherapy approaches. A complete review of clinical trials involving DCs has 
been published recently by Cranmer et al (2004). 
 
Monoclonal antibodies Alone, monoclonal antibodies (mAbs) can target and kill cells via 
induction of antibody-dependent cellular cytotoxicity (ADCC) through the activation of 
complement. mAbs can also be conjugated to cellular toxins or radioisotopes (Scott et al 
1997). Bi-specific mAbs target both tumor antigen and a receptor expressed by desired 
effector cell such as CD20 on B cells or CD3 on T cells. 
 
There are currently several mAbs in clincal trials such as Rituximab for Non-Hodgkins 
lymphoma (McLaughlin 2001), Trastuzumab for breast carcinoma (Baselga 2001)and 131I-
WX-G250 for RCC (Steffens et al 1999). Clinical trials with Rituximab, which targets CD20 
present on 90% of B cell lymphomas, have confirmed its therapeutic effect in low and 
intermediate grade CD20+ Non-Hodgkins lymphoma (McLaughlin et al 1998) and also in 
combination with radioisotopes (Witzig et al 2002). The anti HER2/neu monoclonal antibody, 
trastuzumab, has also shown promise in clinical trials, resulting in a higher rate of objective 
response, longer duration of response, improved 1-year survival, and longer overall survival 
(Slamon et al 2001). Trials of the RCC specific mAb are only at the stage of establishing 
maximal toleratable dose and safety. 
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Gene therapy Gene therapy can be divided into two strategies: corrective gene therapy and 
immunogene therapy. Corrective gene therapy aims to substitute defective genes with their 
functional counterparts. Most corrective gene therapy studies are aimed at tumor cell 
destruction with concomitant antitumor immune responses. Immunogene transfer is based on 
the delivery of DNA encoding immune modulators such as IL-2. Leuvectin® is a plasmid/lipid 
complex encoding human IL-2 (Figlin et al 1999). Clinical trials with Leuvectin have 
demonstrated a markedly reduced systemic toxicity as compared to systemic IL-2 treatment 
(Galanis et al 1999, Belldegrun et al 2001). 
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1.3 AIMS 
 
 
The aims of this thesis are 1) to elucidate the repertoire of immunogenic molecules in RCC 
and 2) to evaluate the potential of identified molecules as diagnostic, prognostic or therapeutic 
targets with relation to RCC. 
 
The first aim is to be achieved through the use of the following methods 1) Suppression 
Subtractive Hybridization (SSH), 2) Serological analysis of recombinant cDNA expression 
libraries (SEREX) and 3) Serum Antibody Detection Array (SADA) analysis.  
 
The second aim is to be achieved by 1) examination of the literature and gene databases for 
known homologies to genes and possible relationship to cancer, 2) examination of the 
expression profiles of identified genes through Northern blotting and RTPCR, 3) examination 
of seroreactivity profiles through secondary SEREX, and 4) examination of immunogenicity 
of derived peptides in a mixed lymphocyte reaction.  
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2. Materials and Methods 
 
 
2.1 RNA 
 
 
2.1.1 Isolation of RNA 
 
Total RNA was isolated from cell lines and tissues using Tri ReagentTM (Sigma, Taufkirchen, 
Germany). Adherent cells were first trypsinized and immediately lysed in Tri ReagentTM  (1ml 
per 5-10x106 cells). Frozen tissue samples from human normal kidney and RCC were first 
pulverised with a membrane disruptor and immediately homogenized and lysed in Tri 
ReagentTM (1ml per 50-100mg of tissue). After 5 minutes of incubation at room temperature, 
200ml chloroform per ml Tri ReagentTM was added. After mixing and incubating for 2-15 
minutes at room temperature the samples were centrifuged for 15 minutes at 13000 rpm at 
40C. The upper phase was transferred to a tube containing 0.5ml isopropanol per ml Tri 
ReagentTM. After mixing and incubating for 5-10 minutes at room temperature, the samples 
were centrifuged for 10 minutes at 13000 rpm at 40C. The RNA pellet was washed with 1ml 
70% ethanol and dried for 5 minutes in a speed-vac. The pellet was dissolved in 50ml 
diethylpyrocarbonate (DEPC)-treated water and stored at -800C. The amount of total RNA 
was determined by measuring the absorbance at 260nm. The total RNA was used for poly A+ 
RNA isolation, reverse transcription-polymerase chain reaction (RT-PCR), northern blotting 
or double strand (ds) cDNA synthesis. 
 
DEPC-treated water:   200ml DEPC per litre distilled water 
     Mix well and incubate overnight at room temperature 
     Autoclave 
 
 
2.1.2 Poly A+ mRNA  preparation 
 
 
Poly A+ mRNA was isolated from total RNA samples with mini-oligo(dT) cellulose spin 
columns (Peqlab, Erlangen, Germany). A maximum of 1mg of total RNA from tumor tissue 
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or cell line in 0.5 M NaCl buffer was applied to a mini-oligo(dT) cellulose spin column. The 
column was then washed with 0.5 M NaCl and 0.1 M NaCl buffers by centrifugation to 
remove the unbound poly A- RNA. Poly A+ mRNA was spin eluted using a buffer without 
NaCl that was prewarmed to 650C. The amount of eluted poly A+ mRNA wsa determined by 
measuring the absorbance at 260nm. 
 
 
Elution buffer:   10 mM Tris-Cl 
     1mM EDTA 
     pH7.5 
 
0.5 M NaCl buffer:   0.5 M NaCl 
     20 mM Tris-Cl 
     5 mM EDTA 
     pH7.5 
 
0.1 M NaCl Buffer:   0.1 M NaCl 
     20 mM Tris-Cl 
     5 mM EDTA 
     pH7.5 
 
 
2.1.3 RNA gel electrophoresis and Northern Blotting 
 
As most RNAs are able to form secondary structures by intramolecular base pairing, RNA 
must be run under denaturing conditions. Denaturation is achieved by adding formaldehyde to 
the gel and loading buffer. Total RNA (20 mg) was loaded on a 1xMOPS/1.2% agarose gel 
containg ethidium bromide and 2.2M formaldehyde. The gel was run for 3 to 4 hours at 80 V 
in 1x MOPS electrophoresis buffer. The gel was examined on a UV transilluminator to 
visualize the RNA. The staining with ethidium bromide (25 mg/ml) causes rRNA molecules to 
appear as sharp bands that can be used as internal markers. In mammalian cells these 
molecules are 28S and 18S, corresponding to 4718 and 1874 nucleotides respectively. 
 
Before blotting, the gel was rinsed in DEPC-treated water to remove formaldehyde. The gel 
was blotted upside down onto a positively charged nylon membrane (HybondTM –N+, version 
2.0; Amersham-Pharmacia, Freiburg, Germany) by overnight capillary blotting with 20xSSC. 
After blotting, the membrane was washed briefly in 2xSSC to remove any adhering agarose 
and air dried for up to an hour. To be able to reprobe the membrane several times, the 
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membrane was UV-crosslinked using the Stratalinker (Stratagene, Amsterdam, The 
Netherlands) and the auto-cross-link program. The membrane was stored dry between sheets 
of WhatmannR 3MM filter paper at room temperature. 
 
 
10xMOPS:    0.4 M MOPS 
     0.1 M Sodium Acetate 
     0.01 M EDTA 
     pH 7.0 
 
20xSSC:    3 M NaCl 
     0.3 M Na3 Citrate 
 
2.1.4 Northern blot hybridisation 
 
Northern blots were prewetted with DEPC-treated water and put into rollerbottles with the 
RNA side of the blot towards the inside of the bottle. Blots were prehybridized at 420C for at 
least 1 hour with 15 ml prehybridization solution containing denatured salmon sperm DNA. 
Probe DNA (~25 ng) was labelled with 50 mCi [a32P]dCTP using RediprimeTM II 
(Amersham). Before adding the denatured probe, 3 ml of 50% dextran sulphate was added to 
the prehybridization solution. Hybridization was performed overnight at 420C. 
 
The next day the blots were washed for 15 minutes in 1xSSC/1%SDS at 420C, 15 minutes in 
0.2xSSC/1%SDS at 420C and 15 minutes in 0.2xSSC/1%SDS at 550C. The blots were sealed 
in plastic wrap and signals were detectable on X-ray film (HyperfilmTM MP, Amersham-
Pharmacia) after 1 hour to 14 days exposure at -800C with intensifying screens. 
 
For reprobing, the blots were stripped in 40 mM Tris-HCL (pH7.5) with 0.1xSSC and 1% 
SDS. For this, the solution was boiled and the blots were washed in this solution for 15 
minutes in a boiling waterbath. 
 
 
 
Prehybridization solution:  50% Formamide 
     1xHybridization buffer 
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     10xDenhardt’s 
     10 mM EDTA 
     0.1%SDS 
     0.2 mg/ml denatured salmon sperm DNA 
 
4xHybridization buffer:  175.32 g/l NaCl 
     73.08 g/l Tris 
     22.08 g/l NaH2PO4 
     64.32 g/l Na2H PO4 
     4 g/l Na-pyro PO4 
     pH 7.5 with HCl 
 
100xDenhardt’s:   1% Ficoll (Type 400) 
     1%polyvinylpyrrolidone 
     1%bovine serum albumin (BSA)(fraction V) 
 
2.1.5 Reverse transcription-polymerase chain reaction (RT-PCR) 
 
 
RT-PCR was performed on total RNA extracted from either normal kidney tissue, tumor 
tissue or cell lines. Reverse transcription was carried out with the following components: 
 
Component Volume 
RNA sample 1mg 
Oligo dT (500ng/ml) 2ml 
ImProm-IITM Reaction buffer 5x 4ml 
MgCl2 , 25 mM 4.8ml 
rRNasinR Ribonuclease Inhibitor (40U/ml) 0.5ml 
ImProm-IITM Reverse Transcriptase (10U/ml) 1.0 ml 
Nuclease-free water Up to 20ml 
# All reagents from Promega  Madison, USA, except Oligo dT. 
 
The template RNA and the OligodT primer (Sigma) were first mixed and heated to 700C for 5 
minutes then immediately chilled on ice. The remainder of the components were mixed 
Materials and Methods   - 36 – 
together on ice and then added to the primer and RNA sample mix. The mix was then 
incubated for 5 minutes at 250C followed by 1 hour at 420C. Finally the reverse transriptase 
was heat inactivated at 700C for 15 minutes. The resulting cDNA was then stored at -200C or 
used immediately for PCR. 
 
 
2.2 DNA 
 
 
2.2.1 DNA transformation of bacteria by heatshock 
 
For one DNA transformation three tubes of competent bacteria were thawed on ice. About 
100 ng of DNA (1-2 ml) was added to one tube of bacteria and mixed by stirring. As a 
negative control 1 ml of sterile distilled water was used and as a positive control 1 ml of Puc18 
DNA (10 ng) was added to the other tubes. The bacteria were incubated on ice for 30 minutes. 
Every 5 minutes the bacteria were carefully mixed by flicking the tube. The bacteria were 
heat shocked for 1 minute at 420C and immediately after put on ice for 2 minutes. 250 ml SOC 
medium (room temperature) was added and the bacteria were incubated shaking at 370C for 
30-45 minutes. 50-100ml of each transformation was spread on LB-agar plates with the 
appropriate selection antibiotic and incubated overnight at 370C. 
 
 
SOC medium:    2% Tryptone 
     0.5% Yeast Extract 
     10 mM NaCl 
     2.5 mM KCl 
     10 mM MgCl2 
     10 mM MgSO4 
     20 mM glucose 
 
 
 
LB medium:    10g/l Tryptone 
     5g/l Yeast Extract 
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     10g/l NaCl 
     pH 7.0 
 
LB agar plates:   LB medium with 1.5% Agar 
 
 
Selection antibiotics:   50 mg/ml ampicillin 
     50 mg/ml kanamycin 
     12.5 mg/ml tetracyclin 
 
 
 
2.2.2 Polymerase Chain Reaction (PCR) 
 
All PCR reactions were carried out with the following components: 
 
Component Volume 
10x PCR buffer 5 ml 
10 mM dNTP mix 1 ml 
50 mM MgCl2 1.5 ml 
Primer mix (10 mM each) 2.5 ml 
Template DNA 10-100 ng 
Taq DNA polymerase (5U/ml) 0.5 ml 
Autoclaved distilled water Up to 50 ml 
# All reagents from Invitrogen 
 
 
 
 
 
 
 
PCR was carried out with the following primer pairs and conditions: 
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Primer pair Sequence 5’-3’ Annealing 
conditions 
Elongation 
conditions 
Cycles Acc. No 
& amplified 
bases  
GAPDH FOR ACCACAGTCCATGCCATCAC 520C x 30 sec 720C x 30 sec 25 BC029340 
GAPDH REV TCCACCACCCTGTTGCTGTA 520C x 30 sec 720C x 30 sec 25 572-1023 
SCP-1 FOR GTACAGCAGAAAGCAAGCAAC 550C x 30 sec 720C x 1 min 30 NM_003176 
SCP-1 REV GGAAATTGGATTCTAAAGCAG 550C x 30 sec 720C x 1 min 30 2095-2652 
TSGA10 FOR GTCTTCTACTAGGGAACTCT 580C x 30 sec 720C x 1 min 30 AF254756 
TSGA10 REV CTCGATTGGCCACCAGCAAA 580C x 30 sec 720C x 1 min 30 2151-2353 
PLU-1 FOR GACACTAAGGACAAGGAGT 580C x 30 sec 720C x 1 min 30 HSA132440 
PLU-1 REV GGACAACCCATTCGACGT 580C x 30 sec 720C x 1 min 30 723-877 
RANBP2L1 FOR GATTGGAAAGGAATCAAGAG 560C x 30 sec 720C x 1 min 30 NM_005054 
RANBP2L1 REV TGGTAACACACAGAACCAT 560C x 30 sec 720C x 1 min 30 5161-5340 
STK31 FOR ATGCAGGCAATCTTATAACA 540C x 30 sec 720C x 1 min 30 BC059374 
STK31 REV GGTCTTCAGAGTGTATTCTA 540C x 30 sec 720C x 1 min 30 841-1100 
BRDT FOR TCAAGAAAGGCACTCAACAG 560C x 30 sec 720C x 1 min 30 NM_001726 
BRDT REV TTCACTACTTGCTTTAACTGC 560C x 30 sec 720C x 1 min 30 544-797 
 
 
 
2.2.3 Small scale DNA isolation from bacteria (miniprep) 
 
 
Bacteria were grown overnight while shaking at 370C in LB medium with the appropriate 
selection antibiotic. 2ml of this bacterial suspension was centrifuged for 1 minute at 
13000rpm. The pellet was resuspended in 250ml P1 solution. Then, 250ml P2 solution was 
added and the suspension was inverted to mix. After the addition of 350ml P3 and mixing by 
inverting, the tubes were centrifuged at 13000rpm for 15 minutes. 850ml of the supernantant 
was transferred to a tube containing 1 ml isopropanol, mixed and centrifuged for 30 minutes 
at 13000rpm. The DNA pellet was then washed with 1 ml 70% ethanol and air dried. The 
pellet was dissolved in 50ml distilled water and the DNA concentration was determined by 
measuring the absorbance at 260nm. 
 
 
 
P1 solution:    50 mM Tris-Cl 
     10 mM EDTA 
     pH 8.0 
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P2 solution :    0.2 M NaOH 
     1% SDS 
 
P3 solution :    2.55 M Kac 
     pH 4.8 
 
2.2.4 Cloning of PCR products 
 
 
PCR products that were amplified with Taq polymerase have 3’ ends with a single 
deoxyadenosine (A) overhang and were directly cloned into the plasmid vector PCRR2.1-
TOPO (Invitrogen, Groningen, Netherlands) which contains single 3’ thymidine (T) 
overhangs. In short, 0.5 to 2 ml PCR product was ligated with 10ng of vector for 5 minutes at 
room temperature. The reaction was stopped with 1 ml stop solution and put on ice. 2 ml was 
added to one vial of One ShotTM competent cells or 50 ml competent bacteria. After incubating 
for 30 minutes on ice, the bacteria were heat shocked (30 seconds at 420C), put on ice for 2 
minutes and incubated for 30 minutes shaking at 370C in 250 ml SOC medium. 50-100 ml 
from each transformation was spread on ampicillin (50 mg/ml) containing agar-plates pre-
incubated with IPTG (40 ml of 100mM solution) and X-gal (40 ml of 40 mg/ml solution) for 
blue-white screening. Plates were incubated overnight at 370C. The next day white colonies 
were picked and grown at 370C in LB medium containing 50 mg/ml ampicillin. 
 
 
2.2.5 DNA digestion with restriction endonucleases  
 
For DNA analysis 1-2mg DNA was digested with various restriction enzymes. The amount of 
enzyme used was according to the manufacturer’s protocol. In general, the digestion was 
performed for 1 hour at 370C in a final volume of 20ml.  
 
 
2.2.6 Cloning of BACE2 into the Uni-ZAPR XR vector. 
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BACE2 cDNA was digested with the restriction enzymes Apa I and Hind III. The adaptors 
B2EcoApa and B2HindXho were then ligated to the digested product for 3 hours at room 
temperature with 1 unit of T4 DNA ligase (Stratagene). The ligated product was then ligated 
into the Uni-ZAPR XR vector and packaged into l phage as described in Packaging and 
Titering (2.3.1.1 Library Construction). 
 
B2EcoApa   5’pAATTCGGCACGAGTG 3’ 
              3’GCCGTGCTCACCCGG 5’ 
 
B2HindXho   5’pAGCTTAGTTCGTCC 3’ 
               3’ATCAAGCAGGAGCT5’ 
 
 
2.2.7 Suppression Subtractive Hybridisation (SSH) 
 
 
With subtractive hybridisation one is able to compare two populations of mRNA and obtain 
clones of genes that are expressed in one population but not in the other. In this case the 
mRNA of RCC tissue and normal kidney were compared. Clones that were differentially 
expressed by the RCC were further analysed by northern blotting and sequence analysis. For 
subtractive hybridisation the CLONTECH PCR-SelectTM cDNA subtraction kit was used. 
This method was originally described by Diatchenko et al in 1996.  
 
 
1. First- and second- strand cDNA synthesis 
 
From both RCC and normal kidney 2 mg of poly A+ RNA was incubated with 10 pmol cDNA 
synthesis primer for 2 minutes at 700C and cooled on ice. First-strand synthesis was 
performed at 420C for 90 minutes with 20 units AMV reverse transcriptase. Directly 
thereafter second-strand synthesis was performed by adding an enzyme cocktail consisting of 
DNA polymerase I (6 units/ml), Rnase H (0.25 units/ml), and E.coli DNA ligase (1.2 units/ml) 
and incubating for 2 hours at 160C. To create blunt ends, 6 units of T4 DNA polymerase were 
added and incubated for another 30 minutes at 160C. The second-strand synthesis was 
terminated by the addition of 1xEDTA/glycogen. The synthesised dscDNA was purified by 
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phenol:chloroform:isoamyl alcohol (25:24:1) extraction and chloroform:isoamyl alcohol   
(24:1) re-extraction and was precipitated by the addition of NH4OAc (final conc. 400 mM) 
and 2 volumes of 100% ethanol. After centrifugation (13000 rpm; 20 min., 40C) the pellet was 
washed with 70% ethanol, air dried and dissolved in 50ml distilled water. To estimate the 
yield and size range of the ds cDNA products synthesized, 6ml of the sample was used for 
agarose gel analysis. 
 
cDNA synthesis primer:  5’TTTTGTACAAGCTT30N-1N3’ 
     (N-1=A, C or G;N = A, C, G or T) 
 
20x EDTA/glycogen:   0.2 M EDTA 
     1 mg/ml glycogen 
 
 
2. RsaI digestion 
 
The remaining 44 ml of the synthesised ds cDNA of both RCC and kidney were digested with 
15 units Rsa I to generate shorter, blunt ended ds cDNA fragments which are of optimal size 
for subtraction and necessary for adaptor ligation. The reaction was terminated with 
1xEDTA/glycogen and Rsa I digestion efficiency was analysed by agarose gel 
electrophoresis. The cDNA fragments were then purified as described for ds cDNA after 
second-strand synthesis. 
 
   
3. Adaptor ligation 
 
To be able to specifically amplify cDNA from RCC after the subtraction of normal kidney 
cDNA, adaptors were ligated only to the Rsa I digested cDNA but not to the normal kidney 
cDNA fragments. The digested cDNA was split into two and ligated to either adaptor 1 or 
adaptor 2R, which was performed overnight at 160C with 400 units T4 DNA ligase. The 
ligation reaction was terminated with 1xEDTA/glycogen and the ligase was heat-inactivated 
(5 min. 720C). Afterwards, ligation efficiency was analysed by a PCR reaction with primers to 
the ligated adaptors and GAPDH primers. 
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Adaptor 1R:       5’CTAATACGACTACTATAGGGCTCGAGCGGCCGCCCGGGCAGGT 3’ 
                                                                                                                                    3’GGCCCGTCCA 5’   
 
 
Adaptor 2R:          5’CTAATACGACTACTATAGGGCAGCGTGGTCGCGGCCGAGGT 3’ 
                                                                                                                                    3’GCCGGCTCCA 5’   
 
 
4. First and second hybridisation 
 
During this procedure, an excess of normal kidney cDNA was added to the RCC cDNA and 
the samples were heat denatured and allowed to anneal. During the first hybridisation the Rsa 
I digested normal kidney cDNA was mixed with either adaptor 1- or 2R-ligated RCC cDNA 
respectively. This hybridisation was performed at 680C for 8 hrs, after denaturation at 980C. 
The remaining ss cDNAs that were available for the second hybridisation were thus enriched 
for differential sequences, as non-target cDNAs present in the RCC and normal kidney cDNA 
form hybrids. The second hybridisation, in which the two samples from the first hybridisation 
were mixed together and to which freshly denatured kidney cDNA was added, was performed 
overnight at 680C. New hybrid molecules with different adaptors on each were formed during 
this step and represented the differentially expressed cDNAs in RCC. 
 
 
5. PCR amplification 
 
Differentially expressed cDNAs were selectively amplified by two PCR reactions. Before 
amplification the missing strands of the adaptors were filled in by a pre-incubation of 5 
minutes at 750C in the presence of Taq polymerase. The first PCR reaction was perfromed 
with primer 1, which can bind to both adaptor 1 and 2R, with 27 cycles at 660C annealing 
temperature. A second PCR reaction with 12 cycles at 680C  annealing temperature was 
performed with two nested primers (1 and 2R), which bind to adaptor 1 and 2R respectively. 
The PCR products after both the first and second PCR reaction were analysed on a 
1xTAE/2% agarose gel containing ethidium bromide. The PCR mixture, containing enriched 
differentially expressed transcripts was then cloned into the PCRR 2.1-TOPO vector (see 
cloning of PCR products). 
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PCR primer 1:   5’CTAATACGACTCACTATAGGGC 3’ 
 
Nested PCR primer 1:  5’ TCGAGCGGCCGCCCGGGCAGGT 3’ 
 
Nested primer 2R:   5’AGCGTGGTCGCGGCCGAGGT 3’ 
 
50xTAE:    242g Tris 
     57.1 ml glacial acetic acid 
     100ml EDTA (pH 8.0) 
 
 
6. Screening 
 
PCR products were then transformed into bacteria (see 2.2.1 DNA transformation of bacteria 
by heatshock). DNA was then prepared (see 2.2.3) from randomly picked colonies and used 
for sequencing. 
 
2.2.8 Sequencing 
 
When sequencing was not performed commercially (MWG Biotech AG, Ebersberg, 
Germany) then it was performed with the ABI PRISM TM 310 GENETIC ANALYZER and 
the BIG DYE TERMINATOR CYCLE SEQUENCING READY REACTION KIT (Applied 
Biosystems). The following primers were used for sequencing: 
 
Primer name Sequence 
M13 rev(-29) CAG GAA ACA GCT ATG ACC 
M13 For GTA AAA CGA CGG CCA GT 
 
For sequencing, 1-2 mg of plasmid DNA was used plus 1.25 mM primer and 2 ml BIG DYE 
mix in a total volume of 20 ml. The mix was then placed in a thermocycler with the following 
program: 
 
  950Cx1min 
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  950Cx30sec 
  450Cx15sec  x40cycles 
  600Cx3.5mins 
  40C hold 
 
The DNA was then precipitated with 2 ml 3 M NaAc (pH 5) and 50 ml 100% ethanol. The 
reaction mix was placed on ice for 10 minutes and then centrifuged for 30 minutes at 13000 
rpm. The DNA pellet was then washed with 70% ethanol and centrifuged again at 13000 rpm 
for 10 minutes. The supernatant was removed by aspiration and the pellet allowed to dry in 
air. The pellet was then resolved in 20 ml Template Suppression Reagent ( Applied 
Biosystems). The sequuence reaction was placed in the ABI PRISM TM 310 GENETIC 
ANALYZER for sequencing. Sequences were analysed using various computer programs (see 
Computer analysis of DNA sequences). 
 
 
2.2.9 Computer analysis of DNA sequences 
 
 
The HUSAR program (Heidelberg Unix Sequence Analysis Resources) was used for analysis 
of DNA sequences (http://genome.dkfz-heidelberg.de/). The following programs within 
HUSAR were used. 
 
Program Use 
Blastn Comparison of nucleotide sequence with nucleotide database 
BlastP Comparison of peptide sequence with protein database 
MAP Finding open reading frames and restriction endonuclease sites 
Translate Translating nucleotide sequence to amino acid sequence 
Malign/Clustal Multiple alignments of sequences 
 
Also the SEREX database was used for comparison with sequences identified in this thesis 
(http://www2.licr.org.CancerImmunomeDB) Ludwig Institute for Cancer Research. 
 
The following program was used for virtual northern blot: Unigene Cluster 
(http://cgap.nci.nih.gov/Genes/GeneFinder) National Institute of Health, USA. 
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2.3 Protein 
 
 
2.3.1 Serological analysis of recombinant cDNA expression libraries (SEREX) 
 
 
The SEREX method was originally developed by Sahin et al. (1995) to identify antigens to 
which patients have a circulating antibody response. For this technique cDNA libraries were 
created from (i) human RCC tissue (U1607), (ii) RCC cell line KTCTL-28 treated with 5-aza 
deoxycytidine (see cells and tissue culture). A human testis library (generated in the same 
manner) was obtained from the lab of Dr. Stefan Eichmüller. The libraries were cloned into 
the Uni-ZAP® XR vector predigested with EcoRI and XhoI and treated with Calf Intestine 
Alkaline Phosphatase (CIAP)  from Stratagene. 
 
2.3.1.1 Library construction 
 
 
First- and second-strand cDNA synthesis 
 
The library construction started with the first strand cDNA synthesis of 5 mg poly A+ RNA 
with 2.8 mg of the cDNA synthesis primer containing an XhoI site. The first strand reaction 
was performed for 1 hour at 370C with 75 units M-MuLV reverse transcriptase. The 
nucleotide mixture for the first strand synthesis contained normal dATP, dGTP and dTTP plus 
the analog 5-methyl dCTP to protect the cDNA from restriction enzymes in the subsequent 
cloning steps. 
 
 
cDNA synthesis primer:  5’GAGAGAGAGAGAGAGAGAGAACTAGTCTCGAG(T)183’ 
 
 
Adaptors:   5’ OH-AATTCGGCACGAG 3’ 
         3’ GCCGTGCTCp 5’ 
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EcoRI adaptor ligation: 
 
The second-strand synthesis reaction was blunt ended by incubating 30 minutes at 720C with 
5 units Pfu DNA polymerase, phenol-chloroform extracted and precipitated. The next day 
EcoRI adaptors were ligated to the blunt ended DNA with 4 units of T4 DNA ligase 
(overnight at 80C) and the adaptor ends were phosphorylated with 10 units T4 polynucleotide 
kinase (30 minutes 370C). 
 
 
EcoRI adaptors:   5’ OH-AATTCGGCACGAG 3’ 
         3’ GCCGTGCTCp 5’ 
 
 
Ligating cDNA into the Uni-ZAP® XR vector 
 
The adaptor-ligated  cDNA was digested with 120 unit XhoI for 1.5 hours at 370C and 
precipitated. Large cDNA molecules were separated from smaller fragments (<0.1kb) by 
CHROMA SPIN-200 DEPC-H2O column chromatography (Clontech). The resulting cDNA 
was phenol-chloroform extracted and precipitated. The next day, 100ng cDNA was cloned 
into 1 mg  Uni-ZAPR XR vector with 2 units T4 DNA ligase (overnight, 160C). 
 
 
Packaging and titering 
 
0.1 to 1.0 mg of ligated DNA was added to one Gigapack III Gold Packaging Extract 
(Stratagene) and incubated for 2 hours at room temperature. Then, 500 ml SM buffer and 
20 ml chloroform were added and the phage suspension was titered. For this purpose, host 
bacteria (XL1-Blue MRF’) were prepared by growing the bacteria to an OD600 of 0.7 to 0.8, 
centrifuging the bacteria for 10 minutes at 500xg and resuspending the bacteria with 10 mM 
MgSO4  to an OD600 of 0.5. Then, 1 ml of undiluted and 1:10 diluted phage suspension was 
added to 200 ml host bacteria and incubated for 15 minutes at 370C to allow the phage to 
attach to the bacteria. 4 ml NZY topagar with 15 ml of 0.5 M IPTG (topagar/IPTG) was added 
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to the bacteria and immediately poured onto NZY agar plates (80 mm). The plates were dried 
for 15 minutes at room temperature and incubated inverted overnight at  370C. The next day 
the number of plaques were counted. 
 
 
SM buffer:    5.8 g/l NaCl 
     2 g/l MgSO4.7H2O 
     50 ml 2% gelatin 
 
 
NZY:     5 g/l NaCl  
     2 g/l MgSO4.7H2O 
     5 g/l yeast extract 
     10 g/l NZ amine (casein hydrolysate) 
     pH 7.5 
 
NZY agar plates :   NZY medium with 1.5% agar 
NZY topagar:    NZY medium with 0.7% agarose 
 
 
Amplifying the Uni-ZAP® XR library 
 
To make a large,  stable quantity of a high titre stock of the library, the library was amplified 
in one round. For this, aliquots of the phage suspension containing 5x104 plaque forming units 
(pfu) was combined with 600ml of host cells (XL1-Blue MRF’; prepared as described 
previously) and incubated for 15 minutes at 370C. For the amplification of 1x106 plaques, a 
total of 20 aliquots were used. After incubation 8 ml NZY topagar/IPTG was added and 
poured onto 150 mm plates. The plates were dried for 15 minutes at room temperature and 
incubated inverted overnight at 370C. 
The next day 8 ml SM buffer was put onto the agar plates and the plates were incubated 
overnight at 40C with gentle rocking. This allowed the phages to diffuse into the SM buffer. 
Then, the bacteriophage suspension was recovered and chloroform was added to a 5% (v/v) 
final concentration. After mixing, the suspension was incubated for 15 minutes at room 
temperature, centrifuged for 10 minutes at 500xg and transferred to a fresh tube. Chloroform 
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was added to a 0.3% (v/v) final concentration and the phage suspension was stored at 40C. 
Small aliquots of the amplified library were stored with 7% (v/v) DMSO at -800C. The titre of 
the amplified library was checked as described previously. 
 
 
Performing plaque lifts 
 
The amplified library was plated on 150 mm NZY agar plates (at least 2 days old) in a 
concentration that the plaques were subconfluent after overnight incubation at 370C. The 
plates were chilled for at least 2 hours to prevent the NZY topagar from sticking to the 
membrane. 
 
For protein screening nitrocellulose membranes (Sartorius AG, Göttingen, Germany) were 
used that were placed onto the plates after 4 hours at 370C. After lifting, the membranes were 
washed in TBST to remove remaining topagar and used immediately for screening. 
 
 
 
TBST:     10 mM Tris-HCl (pH 8.0) 
     150 mM NaCl 
     0.05% Tween 20 
 
 
2.3.1.2 Preabsorption of human serum 
 
 
Preabsorption of the sera is necessary to remove any antibodies that would recognise proteins 
derived from the l phage or from E.coli. The preabsorption was carried out twice for every 
serum for each of the following methods i) preabsorption on a sepharose column ii) 
preabsorption on a nitrocellulose filter. 
 
i) Preabsorption on a sepharose column 
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Protein lysate from E.coli XL1-Blue MRF’ was coupled to CNBr activated Sepharose 4B 
(Pharmacia) according to the manufacturers’ instructions. Initially, host bacteria (XL1-Blue 
MRF’) were prepared by growing the bacteria to an OD600 of 0.7 to 0.8, centrifuging the 
bacteria for 10 minutes at 500xg and resuspending the bacteria with 10 mM MgSO4  to an 
OD600 of 0.5. The bacteria were centrifuged again and resuspended in 20 ml LB medium with 
0.2% maltose and 10 mM MgSO4. 10 ml of this culture was then infected with 5 ml l phage 
without insert (SIST l phage 3.5 x 109 pfu/ml). The other 10 ml was not infected and served 
as a control for the efficiency of the lysis. Both cultures were incubated for 7 hours at 37 0C 
shaking. The cultures were then placed in collodium dialysis bags (Sartorius) and dialysed for 
2 days against 0.1 M NaHCO3 buffer (pH 8.3). Dialysis buffer was changed regularly during 
the 2 days. The dialysate was treated with 0.05% NaN3 to prevent growth of bacteria. Protein 
concentration was measured by absorbance at 280 nm. The efficiency of the lysis could be 
determined by comparing the absorbance of both cultures.  
 
Protein from the dialysate of the infected E.coli XL1-Blue MRF’ was then used for coupling 
to the CNBr-Sepharose matrix (> 5 mg potein /ml gel) according to the manufacturers’ 
instructions.  
 
For preabsorption, sera were diluted 1:1 with PBS and then allowed to flow through the 
Sepharose column at 4 0C with a speed of 0.6ml per minute. The preabsorbed sera were then 
stored for further use at -20 0C with 0.05% NaN3. This preadsorption step was carried out 
twice for every serum. 
 
 
ii) Preabsorption on a nitrocellulose filter 
 
200 ml E.coli XL1-Blue MRF’ (OD600=0.5) was infected with 1 ml l phage without insert 
(SIST l phage 3.5 x 109 pfu/ml). After 15 minutes at 370C, 7 ml of NZY topagar was added  
and then plated on a 145 mm petri dish. Plates were then incubated for 4-6 hours at 370C. 
Then nitrocellulose filters were placed on top and incubated overnight at 370C. The next day 
the filters were removed and then washed 3 x 10 minutes with TBST. The serum to be 
preabsorbed was then added at a dilution of 1:100 or 1:250 and incubated overnight at 40C. 
Finally, the serum was removed and stored at 40C with 0.05% NaN3. This procedure was 
carried out at least twice for each serum. 
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Before reusing the column, reacting antibodies were washed off with 100% solution B for 20 
minutes. This was followed with a wash containing a mix of 31% solution A/69% solution B. 
Then the column was washed with 100% solution A for 10 minutes. Finally the column was 
equilibrated with 100% solution B for storage at 4 0C. 
 
 
Solution A:    0.1 M Glycine, pH 2.7 
     0.1% Sodium Azide 
 
Soultion B:    20 mM Na2HPO4, pH 7.2 
     0.1% Sodium Azide 
 
 
2.3.1.3 Screening of membranes with human serum 
 
Nitrocellulose membranes were blocked by incubating for 1 hour with TBST/5% milk powder 
at room temperature and subsequently washed three times with TBST. Membranes were 
incubated overnight at 40C with 12.5 ml human serum diluted in TBST/5% milk. The 
different libraries were screened with the following sera and dilutions: 
 
    Serum: 
 
Library: 
Autologous 
1:100 
Pooled 
35 patients 
1:100 each 
35 sera 
individually 
1:100 
Patient 3 
1:100 
Patient 7 
1:100 
Patient 20 
1:100 
Total no. 
of plaques 
screened 
U160799 1,500,000 300,000     1,800,000 
KTCTL-
28/dC 
 2,000,000  50,000 50,000 50,000 2,150,000 
Testis   20,000 200,000 200,000 200,000 620,000 
       4,570,000 
After washing three times with TBST, the membranes were incubated with 12.5 ml goat-anti-
human IgG (whole molecule)-alkaline phosphatase antibody (Dianova, Hamburg, Germany; 
1: 20,000 in TBST/5% milk) for 2 hours at room temperature. After three washes with TBST, 
antibody binding was visualised by incubating the membranes for at least 15 minutes with 
BCIP/NBT soultion. The color reaction was stopped by washing the membranes with 
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tapwater. Positive plaques corresponding to positive signals on the membrane were cut out of 
the agar plate, transferred to a microcentrifuge tube containing 500 ml SM buffer and 20 ml 
chloroform, mixed and incubated overnight at 40C. The SM buffer containing the phage 
particles was titered (see Packaging and titering ), a plaque lift was performed and the new 
membrane was rescreened with the same serum. If the new membrane still contained positive 
plaques after this rescreening procedure, one plaque was cut out of the agar as described 
above, which was then used for a) screening with serum from normal donors or other RCC 
patients and b) in vivo excision and subsequent sequence analysis. 
 
 
 
BCIP/NBT solution:   35 ml of 10 ml BCIP (0.5 g in 10 ml 100%           
                                                                                                                     dimethylformamide)  
 
   45 ml of 10 ml NBT (0.5 g in 10 ml 70%  
                            dimethylformamide) 
   in Tris-pH 9.5 
 
 
Tris-pH 9.5   100 mM Tris 
   100 mM NaCl 
   pH 9.5 
   50 mM MgCl2 
 
 
 
 
 
 
In vivo excision using ExAssist helper phage with E.coli strain XLOLR 
 
From the isolated positive phages the pBluescript phagemid was excised from the Uni-ZAP® 
XR vector using the ExAssist helper phage and the E.coli strain XLOLR. The ExAssist helper 
phage contains an amber mutation that prevents replication of the phage genome in a 
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nonsuppressing E.coli strain such as XLOLR cells. Therefore, only the excised phagemid is 
allowed to replicate in the host. In short, host cells (XL1-Blue MRF’ and XLOLR) were 
prepared as described before, but this time the cells were resuspended in 10 mM MgSO4 to an 
OD600 of 1.0. Of these cells, 200 ml XL1-Blue MRF’ cells were combined with 250 ml phage 
stock and 1 ml ExAssist helper phage and incubated for 15 minutes at 370C. Then, 3 ml LB 
medium was added and the tube was incubated for 2.5-3 hours at 370C with shaking. The tube 
was heated to 65-700C for 20 minutes and centrifuged at 1000xg for 15 minutes. The 
supernatant, containing the excised pBluescript phagemid packaged as filamentous phage 
particles, was stored at 40C for up to 2 months. 
 
To plate the excised phagemids, 200 ml of XLOLR cells (OD600 of 1.0) were incubated with 
10 and 100 ml of phage supernatant respectively for 15 minutes at 37 0C. 200 ml of this cell 
mixture was plated on LB-ampicillin (50 mg/ml) agar plates and incubated overnight at 37 0C. 
From these bacteria, DNA was isolated (see DNA isolation from bacteria) and sequence 
analysis was performed (see Sequence analysis). The expression pattern of the isolated genes 
was determined by Northern blot analysis (see RNA gel electrophoresis and Northern 
blotting). 
 
 
 
2.3.2 Serum antibody detection array (SADA) 
 
300 ml of previously identified phage (at 2000 pfu) were placed in duplicate into wells of a 
96-well microtitre plate. 24-26 different phages were used per 96-well plate. The phages were 
then transferred to a rectangle shape agar plate covered 3 hours previously with E.coli XL1-
Blue MRF plus topagar plus 10 mM IPTG. The plates were then incubated overnight at 37 0C. 
The next day the agar plates were incubated with nitrocellulose membranes for 3-4 hours. 
Membranes were then either used immediately for screening with human serum (see 
Screening of membranes with human serum) or stored at -200C. 
 
2.3.3 Peptide synthesis 
 
 
Purified peptides were obtained as lyophilized powder from Dr. R. Pipkorn (Peptide synthesis 
lab, DKFZ, Heidelberg). Peptides were reconstituted in DMSO to a concentration of 10mg/ml 
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and then stored in aliquots of 100ml at –200C. Peptides were diluted to the required 
concentrations with PBS.  
 
The following peptides were predicted to contain the strongest HLA-A2.1 binding motifs 
from the BACE2 protein, by the SYFPEITHI program (http://www.syfpeithi.de). 
 
Peptide Name Peptide Sequence 
BACE2-1 ILLVLIVLL 
BACE2-2 SLSEPILWI 
BACE2-3 LLVLIVLLL 
BACE2-4 ILGLAYATL 
BACE2-5 VLGGIEPSL 
BACE2-6 AILLVLIVL 
BACE2-7 WLLRAAPEL 
 
 
 
2.4 Cells and tissue culture  
 
 
2.4.1 Cell lines 
 
 
Human renal cell carcinoma cell lines, Caki-1, Caki-2, KTCTL-2, KTCTL-28, KTCTL-84, 
KTCTL-128, A-498, 769-p and 786-O were obtained from the tumour bank of the German 
Cancer Research Center. All cell lines were cultured and maintained in RPMI-medium 
supplemented with 10% fetal calf serum (FCS) and antibiotics/L-glutamin (hereafter called 
culture medium) at 37 0C, 5% CO2 in a humidified atmosphere. 
 
Antibiotics/L-glutamine:  100 mg/ml streptomycin sulfate (749 U/mg; Serva,                                             
                                                                                                                     München, Germany) 
  58 mg/ml penicillin G (1730 U/mg; Sigma) 
  245.7 mg/ml L-glutamine (Sigma) 
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2.4.2 Treatment of KTCTL-28 with 5-AZA-CdR 
 
 
In order to increase the chances of identifying cancer-testis related antigens, the RCC cell line 
KTCTL-28 was treated with 5-AZA-CdR. 5-AZA-CdR is a demethylating agent. Genome 
wide demethylation often occurs in cancer cells as well as in testis and results in the 
expression of genes that are normally turned off due to methylation of their promoters. 
Treatment with 5-AZA-CdR (Sigma), was performed as described previously (Coral et al 
1999). Briefly, cells were seeded at a density of 3–4 x 105 cells/ml in a T175 tissue culture 
flask. When cells became firmly adherent to plastic, the medium was replaced with fresh 
medium containing 1 µM  5-AZA-CdR, every 12 h for 2 days (four pulses). At the end of 
treatment, the medium was replaced with fresh culture medium without 5-AZA-CdR, cells 
were cultured for an additional 48 h. mRNA was then isolated (see 2.1.1 isolation of mRNA) 
and used for the creation of cDNA for the construction of a l-phage library or stored at –800C 
for future use in northern blotting or RT-PCR. 
 
 
2.4.3 Generation of human dendritic cells (DCs) from peripheral blood monocytes 
 
 
50 ml fresh human blood was diluted 1:1 with sterile PBS, carefully layered on Ficoll 
(Histopaque®-1077, Sigma) and centrifuged for 20 minutes at 2000 rpm at room temperature. 
The peripheral blood lymphocytes (PBL)-containing interphase was collected and washed 
twice with sterile PBS. Cells were finally resuspended in Iscove’s medium supplemented with 
10% autologous serum, and incubated for 1.5 hours in an incubator (37 0C, 5% CO2 in a 
humidified atmosphere). Nonadherent cells were removed by carefully washing the culture 
medium. Remaining adherent cells were incubated for 10 days in Iscove’s medium 
supplemented with 10% autologous serum, 150 U/ml rhGM-CSF (Strathmann Biotech, 
Hannover, Germany), 50 U/ml rhIL-4 (Strathmann), 50 U/ml rhIFNg and antibiotics/L-
glutamine. Every 2-3 days, the culture medium was refreshed. Maturity of DCs after 9-11 
days of culture was confirmed by microscopy (veiled cells) and/or flourescent activated cell 
sorter (FACS) analysis. 
 
2.4.4 Proliferation assay: PBL activated by peptide loaded DCs 
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Mature DCs were loaded with varying concentrations of synthetic MHC class I-binding 
peptides of the BACE2 proteins for 1.5 hours in 24 well plates at 370C and subsequently 
washed. Autologous PBL, put into culture 2 days before with 10 U/ml rhIL-2 (Strathmann), 
were added to the loaded DCs at ratios between 10:1 and 100:1 (PBL:DC) and cocultured for 
3 days. 150 mCi [3H]-Thymidine (Amersham-Pharmacia) was added to each well and 
incubated overnight at 370C. The next day cells were harvested using a cell harvester (Wallac, 
Freiburg, Germany) and radioactivity was measured in a liquid-scintillation b-counter 
(Pharmacia). 
 
 
2.4.5 FACS analysis 
 
 
For flow cytometry, 3-5x105 cells per well (96 well round bottom microtiter plate) were 
stained with primary antibody in a volume of 50 ml for 1 hour at 40C, then washed three times 
with PBS. Afterwards, cells were incubated with flourescent- labelled secondary antibody ( 
50 ml) for 30 minutes at 40C in the dark and subsequently washed 3 times in PBS. The 
following primary antibodies were used; OKT4 (anti-human CD4), OKT8 (anti-human CD8), 
BB7.2 (anti-human HLA-A2.1), W6/ 32 (anti-human MHC class I), anti-human CD80 (BD 
Biosciences, Heidelberg, Germany) and anti-human CD86 (BD Biosciences). Secondary 
antibodies used were; Flourescein (FITC) labelled rat anti-mouse IgG or FITC labelled rabbit 
anti-rat IgG. Analysis was performed using a FACSCalibur and CellQuest software (BD 
Biosciences). 
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3. Results 
 
 
3.1 Suppression Subtractive Hybridization 
 
 
Suppression subtractive hybridization (SSH) is a technique used for the identification of 
differentially expressed genes. Because upregulation of genes can induce antibody responses 
it was thought that SSH would be a suitable technique for the identification of RCC associated 
antigens. A previous SSH performed on a single RCC patient in this lab had identified the 
MAGE-9 gene. In this study, a pool of 6 RCC versus the matched pool of normal kidney 
tissue was used for SSH. This second SSH served two purposes 1) to confirm the findings and 
reliability of the first SSH and 2) to increase the chances of identifying more upregulated 
genes. 
 
Over 100 clones were initially picked and sequenced. After eliminating duplicated sequences 
and sequences too short for a significant match in the database, 47 clones were left. Six of the 
47 had already been identified by a previous SSH in this laboratory i.e. insulin-like growth 
factor binding protein-3 (IGFBP3), ceruloplasmin, angiopoietin-related protein 2 (ARP2), 
autotaxin (ATX), vascular endothelial growth factor (VEGF) and cyclin D1. The remaining 
41 genes were examined for their expression in the 6 RCC samples and corresponding normal 
kidneys by Northern blotting. Differential expression of 12 of the 41 genes could be 
confirmed by Northern blotting (Table 6). 
 
Clone no. Identity Expression pattern 
4 Suppressor of Ty (SUPT5H) Strong upregulation in 2/6 
9 Ribosomal protein S2 Weak upregulation in 1/6 
10 Unknown/ BAC RP11-674J14 Weak downregulation in 1/6 
16 Unkown/ homologous to mouse clone an01-h01 Weak downregulation in 1/6 
18 Okadoic acid-inducble and cAMP regulated 
phosphoprotein 19 (ARPP-19) 
Strong upregulation in 2/6 
Strong downregulation in 2/6 
22 Ribosomal protein L8 Weak upregulation in 1/6 
36 Adenosine Deaminase (ADA) Weak upregulation in 1/6 
47 Laminin receptor homolog Weak upregulation in 1/6 
48 Beta-site APP-cleaving enzyme (BACE2) Strong upregulation in 2/6 
49 Diubiquitin (UBD) Weak upregulation in 1/6 
80 Unknown/ KIAA1253 Weak upregulation in 1/6 
89 Mitochondrial DNA Weak downregulation in 1/6 
Table 6. Differential expression of SSH clones. 
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As only minor differences could be seen for 9 of the 12 genes these genes were excluded from 
further analyses. Expression levels of the ARPP-19 gene varied widely between normal 
kidney tissues and was also eliminated from further study. The two remaining genes, 
suppressor of Ty (SUPT5H) and beta-site APP-cleaving enzyme (BACE2) were found to be 
strongly upregulated in 2 of the 6 patients each (Figure 4). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Expression by Northern blot analysis of BACE-2 and SUPT5H. 
Shown are the 6 patients from which the SSH library was derived; (N) = normal kidney, (T) = 
RCC tissue. Northern blots were stripped and reprobed with GAPDH as a loading control. 
 
 
3.1.1 Correlation of expression with histology, grading and staging 
 
 
To be useful as a prognostic or diagnostic marker, overexpression of a gene would have to 
correlate with patient outcome or the histology, grading or staging of the tumor. It was 
therefore decided to examine the expression of the two overexpressed genes (BACE2 and 
SUPT5H) as well as nine other differentially expressed genes previously found by an SSH in 
this laboratory in a panel of 35 RCC patients of which the tumor histology, grading and 
BACE-2 
SUPT5H 
GAPDH 
N N N N N N T T T T T T 
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staging is known. The nine other genes previously identified are: semaphorin G (SemG), lysyl 
oxidase (LO), autotaxin (ATX), angiopoeitin-related protein (ARP2), ceruloplasmin (CP), 
vascular endothelial growth factor (VEGF), C1 respiratory complex (C1-RC), cyclin D1, and 
insulin-like growth factor-binding protein-3 (IGFBP3). Samples of the Northern blots can be 
seen in Figure 5. The resulting expression profile of the 11 genes in 35 patients is depicted in 
Figure 6 which groups the patients according to histological subtype. 
 
Statistical analysis of the correlation of differential gene expression with tumor histology, 
grading and staging is shown in Table 7. Apart from the clear-cell group, the number of 
patients per group in the other histological types was too small to allow a statistical analysis 
between these groups. However, they could be compared to the group of clear-cell RCC. The 
clear-cell RCC group could be compared to all non-clear-cell RCC. For some of the genes, 
namely C1-RC, SUPT5H, VEGF, ARP2, ATX, LO and Sem G, there appears to be a 
correlation with histological subtype. Overexpression of these genes has been found mainly in 
clear cell RCC. BACE2 on the other hand is preferentially overexpressed in mixed (clear and 
granular) and oxyphil. There was no correlation of gene overexpression with tumor grading 
and only ATX and LO showed a correlation with tumor progression. Correlation with patient 
outcome/ survival will be performed after a 5 year period to determine if any of the genes 
have prognostic significance. 
 
 
3.1.2 Testing the immunogenicity of BACE2 
 
 
Immune responses of the T helper (CD4+) and T cytotoxic (CD8+) type were examined for the 
BACE2 protein. The existence of T helper responses was assayed indirectly by looking for the 
presence of anti-BACE2 antibodies in the sera of RCC patients. This was achieved by 
expressing the BACE2 protein in l-phage and performing a secondary SEREX with this 
phage. No antibodies could be detected in the sera of 35 RCC patients nor in 15 healthy 
controls 
 
Seven peptides derived from BACE2 and predicted to bind HLA-A2.1 were assayed in a 
mixed lymphocyte culture test for their ability to induce CD8+ T cell proliferation. None of 
the peptides examined were found to induce proliferation in 3 donors. 
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GAPDH 
VEGF 
LO 
IGFBP3 
CyclinD1 
CP 
C1-RC 
ARP2 
Figure 5. Expression by Northern blot analysis of ARP2, C1-RC, CP, CycD1, IGFBP3, 
LO, and VEGF. 
Shown are the 6 patients from which the SSH library was derived; (N) = normal kidney, 
(T) = RCC tissue. Northern blots were stripped and reprobed with GAPDH as a loading 
N N N N N N T T T T T T 
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3.2 SEREX 
 
 
As none of the genes identified by SSH could be classed as antigens (with the exception of 
MAGE-9), it was decided to screen for antigens by the SEREX method. Clones identified by 
the SEREX method are by definition immunogens as they have already induced a B-cell  
response which implies T-cell help. Three different libraries were screened in this study; i) a 
library derived from a tumor of a patient, ii) a library from a RCC cell line treated with 5-aza 
deoxycytidine and iii) a testis library. The libraries were screened either with autologous 
serum ( in the case of the patient tumor library), pooled serum ( in the case of the patient 
tumor library and the cell line library), or with various individual sera (in the case of the testis 
library. All positive phages were tested twice to ensure no false positives. Plaques were then 
subcloned to monoclonality and in vivo excised. The resulting phagemid was sequenced and 
each sequence was compared to the genome database (www.ncbi.nlm.nih.gov) and to the 
SEREX database (www2.licr.org/CancerImmunomeDB). Selected clones were then analyzed 
for mRNA expression and seroreactivity. 
 
 
3.2.1 Screening of a patient tumor library with autologous and pooled sera 
 
 
A phagemid library was constructed from RNA isolated from the tumor of a 72 year old 
female with Renal Cell Carcinoma. The tumor was of the mixed type and the staging of the 
tumor was defined as T1G1. The mRNA for the genes IGFBP3 and BACE 2 were found to be 
upregulated in this patient but not SemG, SUPT5H, ATX, LO, C.1., VEGF, ARP2, 
Ceruloplasmin or CyclinD1. 
 
Approximately 1.5 x106 plaques from this library were screened initially with serum from the 
same patient. 83 clones were identified as potential positives. 23 of these could be discounted 
immediately as they were directly interacting with the secondary antibody. The remaining 60 
could not be verified by rescreening. 
 
Pooled serum from 33 patients with RCC was then used to screen 3x105 clones. 17 clones 
were initially identified. However only 5 of these could be verified after rescreening. The 
clones were named HD-RCC-1 to HD-RCC-5 according to SEREX terminology (Table 8). 
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HD-RCC- 1, 2, 3 and 5 all represent novel genes. HD-RCC-4 contains part of the sequence of 
NADH Ubiquinone Oxidoreductase chain5. Examples of SEREX membranes are shown in 
Figure 7.  
 
 
Clone Accession no. Identity SEREX homologs 
HD-RCC-1 
 
HD-RCC-2 
AC008009 
 
HS1056L3 
DNAJ domain containing 
protein 
No homologies 
None 
 
None 
HD-RCC-3 AC005383 Actin associated filament 
protein 
None 
HD-RCC-4 BQ614315 NADH Ubiquinone 
Oxidoreductase chain 5 
None 
HD-RCC-5 BC012607/ AC006559 Translocation between 
Chr.19q13.2 and Chr.12p12 
None 
 
Table 8. Clones identified from screening of a tumor library with pooled patient sera. 
 
 
 
 
 
 
 
 
Figure 7. Developed SEREX membranes. 
A) positive/negative control, B) Initial identification of clone HD-RCC-1, C) Secondary 
SEREX of HD-RCC-1 with ~50% negative phages. 
 
 
HD-RCC-1 has a sequence of 1270 bp and can be localised to chromosome 3q26.2-27 
(AC008009). The gene consists of at least 5 exons. Analysis of the sequence reveals an open 
reading frame of 345 bp  which results in an a.a. seq of 115 aa (Figure 8). No translation 
A B C 
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initiation site could be identified but it cannot be far from the 5 prime end as Northern blot 
analysis reveals a transcript of between 1300 and 1400 bp. Comparison of the a.a. sequence 
with sequences in the database reveals a 60% homology to DNA J domain containing 
proteins. These proteins belong to the family of molecular chaperones of which heat shock 
proteins are a large part. It has been shown that hsp27 is upregulated in RCC. Also 4 different 
molecular chaperones have previously been identified by the SEREX method in RCC. 
 
HD-RCC-2 has a sequence of 800bp and is localised to chromosome 1p35-36 (HS1056L3). 
Hybridization of this clone to Northern blots reveals a transcript of approximately 4 kb. 
Sequencing of an IMAGE clone of 3kb which overlaps the clone we have isolated reveals an 
ORF of at least 2 kb which terminates prior to the beginning of the clone isolated by SEREX. 
Therefore the clone isolated lies in the 3 prime untranslated region of the gene. Therefore the 
immunogenicity of this clone cannot be related to the gene from which it comes. However the 
sequence of the clone shares some homology with another unknown sequence on 
chromosome 3 and this sequence may somehow be immunogenic. 
 
HD-RCC-3 has a sequence of 3660 bp and is localized to chromosome 10q25.1 (AC005383). 
It consists of 19 exons with 2 possible alternative splicing sites. Hybridization to Northern 
blots reveals a transcript of about 4 kb. Depending on the splicing the open reading frame is 
either 2451bp or 2652bp resulting in an aa sequence of 817/884 aa’s (Figure 9). Sequencing 
of this clone revealed that the 2451 splice variant is the one expressed in the tumor from 
which the library was derived. Comparison of the aa sequence with the databases reveals a 
40% homology to actin associated filament proteins. 
 
HD-RCC-4 was identified as NADH Ubiquinone Oxidoreductase chain 5. However the 
sequence isolated belongs to the 3 prime untranslated region of the gene. Analysis of the aa 
sequence of the clone reveals a 54% homolgy to Epstein Barr Virus and this homology may 
be the cause of the positive reaction found. It is quite possible that one of the 33 patients had 
an EBV infection and antibodies toward this in the patients serum may have reacted with the 
clone we have isolated. 
Sequencing of HD-RCC-5 reveals a different sequence at the 5 prime end than at the 3 prime 
end. The sequence at the 5 prime end belongs to chromosome 19 and the 3 prime end is from 
chromosome 12. Therefore this clone could be from a translocation between chromosome 19 
and 12. The 5 prime end corresponds to a clone (BC012607) which is similar to pregnancy 
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specific beta-1-glycoprotein 5. However, in the SEREX clone, the gene is in the negative 
orientation. There are no significant open reading frames of the reverse strand of the 
pregnancy specific clone. The 3 prime end, which corresponds to a region of chromosome 
12p12 (AC006559), contains an open reading frame of 126 aas. There were no open reading 
frames found as a result of the translocation. Therefore, the antibodies detected against this 
clone must be directed against the 12p12 part of the clone. 
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mRNA: 
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1260bp 
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Identity:  60% aa homology to DNA-J domain containing proteins 
Figure 8. Localisation and Characterisation of HD-RCC-1 
SEREX 
   clone:
Chr. 10q25.1
mRNA: 
Peptide: 
Identity: 
Exons: 
ORF: 
111 kb 
63kb 
4260 bp 
4463 bp 
3690bp 
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2652 bp 
 
817 aa 
884 aa 
40% homology on the aa level to actin associated filament proteins. 
Figure 9. Localisation and Characterisation of HD-RCC-3 
SEREX 
   clone: 
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3.2.1.1 mRNA expression and seroreactivity of HD-RCC-1 to 5 
 
 
The mRNA expression of each clone was examined by Northern blotting or RT-PCR. 
Seroreactivity was examined by secondary SEREX i.e. the isolated clones were plated ~50:50 
with negative clones followed by incubation of the membrane with individual sera. Table 9 
summarizes the results of the mRNA expression and seroreactivity of each of the clones. 
 
 
Clone mRNA expression Seroreactivity 
Patient        Normal 
HD-RCC-1 n.d.  1/35 0/15 
HD-RCC-2 n.d. 1/35 0/15 
HD-RCC-3 n.d. 1/35 0/15 
HD-RCC-4 n.d. 1/35 0/15 
HD-RCC-5 Restricted to the tumor from which the library was derived 1/35 0/15 
 
Table 9. mRNA expression and seroreactivity of HD-RCC-1 to 5. n.d. No differential 
expression between normal kidney and RCC. 
 
 
For clones HD-RCC-1,to –4, no difference in mRNA expression could be seen between 
normal kidney and RCC tumor. For HD-RCC-5, only the patient from which the library was 
derived expressed the translocation product. For all cases, only 1 in 35 patients had reactive 
antibodies (in each case a different patient). Serum from 15 healthy donors did not react to 
any of the clones. 
 
None of the above clones are therefore suited to immunotherapy as they are either uniformly 
expressed or restricted to an individual patient. Also, only 1 out of 35 patients reacted to any 
of these clones. It was decided not to analyse these clones any further. 
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3.2.2 Screening of a RCC cell line library with pooled sera 
 
 
A l-phage library was constructed from the RNA from the RCC cell line KTCTL-28 treated 
with 5-aza-2’-deoxycytidine (5-AZA-CdR). 5-AZA-CdR is a hypomethylating agent. 
Treatment with 5-AZA-CdR has been shown to increase the expression of cancer testis 
antigens (Coral et al 2002). Approximately 2x106 plaques from this library were screened 
with pooled sera. A total of 20 positives were initially identified. However, only 6 of these 
could be confirmed after rescreening. These 6 clones are named HD-RCC-6 to HD-RCC-11 
(Table 10).  
 
 
Clone Accession no. Identity SEREX homologs 
HD-RCC-6 
HD-RCC-7 
NM_152233 
NM_002078 
Sorting nexin 6 (SNX6) 
Golgin subfamily a, 4 (GOLGA4) 
NY-BR-48 
Hom-Br2-54 HOM-
MA1-12 HOM-MA1-8 
MO-CO-134 MO-CO-
77 NGO-St-67 se20-7 
HD-RCC-8 NM_003472 DEK proto-oncogene (DEK) None 
HD-RCC-9 BC013724 Human ferritin, heavy chain  None 
HD-RCC-10 
 
 
HD-RCC-11 
NM_018003 
 
 
NM_152255 
Uveal autoantigen (UACA) 
 
 
Proteosome subunit, alpha type 7 
(PSMA7) 
MO-BC-423; MO-BC-
440; NY-ESO-12; MO-
CO-80; MO-TES-217 
None 
 
Table 10. Clones identified from screening of the KTCTL-28/5-AZA-CdR library with 
pooled patient sera. 
 
 
HD-RCC-6 encodes a member of the sorting nexin family. Members of this family contain a 
phox (PX) domain, which is a phosphoinositide binding domain, and are involved in 
intracellular trafficking. Sorting nexin 6 (SNX6) associates with the long isoform of the leptin 
receptor, the transforming growth factor-beta family of receptor serine-threonine kinases, and 
with receptor tyrosine kinases for platelet-derived growth factor, insulin, and epidermal 
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growth factor. SNX6 may form oligomeric complexes with family member proteins through 
interactions of both the PX domain and the coiled coil regions of the molecules (Parks et al 
2001). Translocation of this protein from the cytoplasm to the nucleus occurs after binding to 
proviral integration site 1 protein (Ishibashi et al 2001). This gene results in two transcripts 
encoding two distinct isoforms. Sequencing of the SEREX clone revealed that HD-RCC-6 
corresponds to the shorter isoform. SNX6 has been identified previously as an antigen in the 
screening of a breast cancer sample with autologous serum. No mutations could be identified 
in the sequencing of the clone. 
 
Golgin subfamily a, 4 (GOLGA4) is a member of the golgin family of proteins which are 
localized to the golgi apparatus. GOLGA4 is thought to play a role in Rab6-regulated 
membrane-tethering events in the Golgi apparatus (Barr,F.A 1999). Alternative splice variants 
have been described but their full-length nature has not been determined. GOLGA4 is also 
known to be an autoantigen (Kooy et al 1992) and has been identified in seven other SEREX 
studies to date. There were no mutations in the HD-RCC-7 clone as compared to the database. 
DEK is a 43-kDa phosphoprotein that was first isolated as part of a fusion protein expressed 
in a subtype of acute myeloid leukemia (AML). The fusion protein is a result of a (6;9) 
chromosomal translocation resulting in the chimeric dek-can fusion protein (von Lindern et al 
1992). Its role in leukemia, however, is unclear. DEK itself has been identified as an 
autoimmune antigen in patients with pauciarticular onset juvenile rheumatoid arthritis, 
systemic lupus erythematosus, and other autoimmune diseases (Szer et al 1994, Dong et al 
1998, Wichmann et al 2000). DEK has been reported to be a site-specific DNA binding 
factor, which recognizes a specific DNA element in the HIV-2 enhancer (Fu et al 1997). 
Again, no mutations could be identified in the HD-RCC-8 clone. 
 
Human ferritin is a major tissue iron-binding protein (Hann et al 1980) and, in its native form, 
is approximately 500 kDa. It is composed of 24 subunits consisting of acid/heavy (H) and 
basic/light (L) chains (Arosio et al 1979, Theil et al 1987). The genes encoding H- and L-
ferritin are found in different chromosomes and are transcriptionally independent (McGill et 
al 1987). The 24-subunit polymer may form isoferritins, which are either more acidic (H-rich) 
or more basic (L-rich), depending on the relative proportions of H and L chains. It has been 
shown that H-ferritin from melanoma cells may suppress immune responses and that this 
immunosuppression is attributable to changes in antigen presenting cells, which resulted in 
the preferential activation of regulatory T cells that produce interleukin 10 (IL-10) (Gray et al 
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2001, Gray et al 2002). The human ferritin heavy chain has not been previously identified by 
SEREX. The HD-RCC-9 clone does not contain any mutations as compared to the database. 
 
The human uveal autoantigen (UACA: uveal autoantigen with coiled coil domains and 
ankyrin repeats) has only recently been identified (Yamada et al 2001). Its function is 
unknown. However, autoantibodies against UACA appear to be more prevalent in people with 
panuveitis (Yamada et al 2001). Several other SEREX studies have identified UACA with 
seroreactivity in normal healthy controls ranging from 50% to 100% depending on the study. 
No mutations were identifed in the sequence of the HD-RCC-10 clone. 
 
The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S 
core structure. The core structure  is composed of 4 rings of 28 non-identical subunits; 2 rings 
are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes 
are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an 
ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a 
modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. The 
proteosome subunit, alpha type 7 (PSMA7)gene encodes a member of the peptidase T1A 
family, that is a 20S core alpha subunit. This particular subunit has been shown to interact 
specifically with the hepatitis B virus X protein, a protein critical to viral replication (Huang 
et al 1996). In addition, this subunit is involved in regulating hepatitis virus C internal 
ribosome entry site (IRES) activity, an activity essential for viral replication (Kruger et al 
2001). This core alpha subunit is also involved in regulating the hypoxia-inducible factor-
1alpha, a transcription factor important for cellular responses to oxygen tension (Cho et al 
2001). Multiple isoforms of this subunit arising from alternative splicing may exist but 
alternative transcripts for only two isoforms have been defined. PSMA7 itself has not been 
previously identified by SEREX, however another subunit (PSMA6) has been found 3 times 
with seroreactivity against PSMA6 two to three times as frequent in patients with malignant 
stomach cancer as in normal healthy controls. No mutations were identified in the HD-RCC-
11 clone. 
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3.2.2.1 mRNA expression and seroreactivity of HD-RCC-6 to 11 
 
 
Northern blotting of the 6 clones showed no differences between normal kidney and RCC 
tumors of 10 patients. However, mRNA for the human ferritin heavy chain was upregulated in 
the 5-AZA-CdR treated KTCTL-28 line as compared to non-treated KTCTL-28. Results of 
seroreactivity and mRNA expression are summarized in Table 11. 
 
 
Clone mRNA expression Seroreactivity 
Patient        Normal 
HD-RCC-6 n.d.  1/35 0/15 
HD-RCC-7 n.d. 35/35 15/15 
HD-RCC-8 n.d. 1/35 0/15 
HD-RCC-9 n.d. Upregulated in 5-AZA-CdR treated KTCTL-28 1/35 0/15 
HD-RCC-10 
HD-RCC-11 
n.d. 
n.d. 
35/35 
1/35 
15/15 
0/15 
Table 11. mRNA expression and seroreactivity of HD-RCC-6 to 11. n.d. No differential 
expression between normal kidney and RCC. 
 
 
Apart from HD-RCC-7 (GOLGA4) and HD-RCC-10 (UACA), the seroreactivity of the 
clones identified is restricted to 1/35 patients (in each case a different patient). GOLGA4 and 
UACA appear to be strong autoantigens and antibodies against these genes has no correlation 
with disease state. 
 
 
3.2.3 Screening of a RCC cell line library with individual sera 
 
 
The 5-AZA-CdR treated KTCTL-28 cell line was then screened with sera from 3 individuals. 
0.5x105 plaques were screened with each of the 3 sera. 10 clones were initially identified of 
which only 5 could be confirmed after rescreening. Of these 5, 2 clones corresponded to the 
same gene. Table 12 lists the clones identified in this screening. 
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Clone Accession no. Identity SEREX homologs 
HD-RCC-12 
HD-RCC-13 
NM_006793 
BC012423 
Peroxiredoxin 3 (PRDX3) 
Superoxide dismutase 2 (MnSOD) 
None 
None- 
HD-RCC-14 NM_005751 A kinase anchor protein 9 
(AKAP9) 
MO-REN-1 
HD-RCC-15 BC012579 KIAA1229/ unknown protein None 
Table 12. Clones identified from screening of the KTCTL-28/5-AZA-CdR library with 3 
individual patient sera. 
 
 
Peroxiredoxin 3 (Prdx3) expression is induced by oxidants in the cardiovascular system and is 
thought to play a role in the antioxidant defense system and homeostasis within the 
mitochondria (Araki et al 1999, Wonsey et al 2002). Prdx3 is a c-myc target gene, and 
antisense experiments have shown that its expression is required for neoplastic transformation 
by c-myc (Wonsey et al 2002). Prdx3 has been shown to be overexpressed in hepatocellular 
carcinomas (Choi et al 2002). Prdx3 has not been previously identified by SEREX, however 
another family (Prdx1) member has been identified in the screening of a melanoma cell line 
with serum from melanoma patients. 
 
Superoxide dismutase 2 (SOD2), also known as manganese-dependent superoxide dismutase 
(MnSOD), is the mitochondrial scavenger of O2-. Its activity has been shown to be 
dramatically reduced in several classes of malignancies, including melanoma, 
hepatocarcinoma and breast cancer (Sun 19990). On the other hand, overexpression of 
MnSOD has been shown for neuro-epithelial (Landriscina et al 1996), ovarian (Ishikawa et al 
1990), cervical (Nakano et al 1996) and thyroid tumors (Nishida et al 1993), with MnSOD 
levels correlating with tumor severity. These differences in response to MnSOD may be due 
to different constitutive levels of MnSOD and may also be dependent upon the cell type. 
Neither MnSOD nor any of its family members have been identified before by SEREX. An 
analysis of RCC patients using the SERPA technique has identified increased levels of anti-
MnSOD antibodies in 4 out of 6 RCC patients (Unwin et al 2003).  
 
The A-kinase anchor protein 9 (AKAP9) is a member of a group of structurally diverse 
proteins which have the common function of binding to the regulatory subunit of protein 
kinase A (PKA) and confining the holoenzyme to discrete locations within the cell. Alternate 
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splicing of this gene results in many isoforms that localize to the centrosome and the Golgi 
apparatus, and interact with numerous signaling proteins from multiple signal transduction 
pathways. AKAP9 also known as yotiao is a scaffold protein that physically attaches type I 
protein phosphatase (PP1) and PKA to N-methyl-D-aspartate (NMDA) receptors to regulate 
channel activity (Westphal et al 1999). AKAP9 has been identified before by SEREX in the 
screening of a RCC tumor with autologous serum. 
 
HD-RCC-15 corresponds to a protein of unknown function (KIAA 1229). The KIAA 1229 is 
located on chromosome 1p22.3 and has 57% sequence similarity on the amino acid level with 
a human reverse transcriptase homolog (accession no. S65824). Virtual Northern blotting of 
KIAA 1229 shows that it is expressed in many normal tissues 
(http://cgap.nci.nih.gov/Genes/GeneFinder). KIAA 1229 has not been identified previously by 
SEREX.  
 
 
3.2.3.1 mRNA expression and seroreactivity of HD-RCC-12 to 15 
 
 
The mRNA expression of the four clones was analysed by Northern blotting. No differential 
expression could be found for any of the clones in 24 RCC patients. The seroreactivity of the 
clones was then analyzed with 35 patient sera and 15 healthy controls. The results are 
summarized in Table 13.  
 
 
Clone Identity Seroreactivity 
Patient        Normal 
HD-RCC-12 PRDX3 4/35 1/15 
HD-RCC-13 MnSOD 5/35 0/15 
HD-RCC-14 AKAP9 12/35 9/15 
HD-RCC-15 KIAA1229 3/35 1/15 
 
Table 13. Seroreactivity of HD-RCC-12 to 15 in RCC patients and healthy controls.  
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For 3 of the above antigens (PRDX3, AKAP9, KIAA1229), there is little difference in 
seroreactivity between RCC patients and healthy controls. Therefore these antigens are 
unsuitable as prognostic, or diagnostic markers.  
 
In the case of MnSOD, 5 out of 35 patients have antibody responses against this protein 
whereas none of the healthy controls are reactive. This makes MnSOD a good candidate for 
prognostic or diagnostic purposes.  
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3.2.4 Screening of a Testis library with individual sera 
 
 
A testis library was obtained from the laboratory of Stefan Eichmüller (Skin Cancer Unit, 
DKFZ, Heidelberg) and screened with individual sera from 35 RCC patients. Initially 2x104 
plaques were screened with each of the 35 sera. Thereafter the top 3 responding patients (top 
3 sera with the most reactive clones) were used to screen the testis library further. 2x105 
plaques were screened with each of the 3 sera. In total, 104 clones were identified; 15 from 
serum no.3, 30 from serum no. 7, 33 from serum no. 20, and 26 from all others combined. The 
104 clones corresponded to 59 different transcripts, 20 of which belong to unknown genes. 
Table 14 lists the 59 different transcripts. Clones are ordered according to the serum with 
which they were identified (3, 7, 20, all others, respectively). 
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Table 14. Clones identified from screening of a testis library with 35 individual patient sera. 
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Table 14. Continued. 
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3.2.4.1 Sequence analysis of HD-TES-1 to 59 
 
 
The PubMed database was examined for literature on all the known clones. From this, the 
antigens are predicted to belong to the following categories according to their predicted 
expression: Cancer-Testis antigens, Restricted expression antigens, Upregulated antigens, 
Normal/ ubiquitous antigens (autoantigens), and Unknown antigens. 
 
Cancer-Testis antigens Six of the clones identified here are predicted to be expressed only in 
testis tissue. The six clones (HD-TES-4, 14, 27, 30, 31 and 55) correspond to RAN binding 
protein 2 like-1 (RANBP2L1), TSGA10, PLU-1, serine/ threonine kinase 31 (STK31), 
Bromodomain testis specific protein (BRDT), and SCP-1 meiosis specific protein, 
respectively. RANBP2L1 has been identified 5 times in this screening, four times from one 
serum and once with another. It has also been identified in other SEREX studies. TSGA10 has 
been isolated here 3 times from the same serum. No other SEREX studies have identified 
TSGA10 as an antigen before. PLU-1 has already been suggested to be a cancer-testis antigen 
and has been shown to be upregulated in breast cancer (Barret et al 2002). It has not been 
identified before as an antigen for RCC. STK31 has been identified 17 times with the one 
serum in this screening possibly indicating high immunogenicity of this protein in this patient. 
It has not been found by other SEREX studies. BRDT has been identified as a cancer-testis 
antigen in lung cancer (Scanlan et al 2000). It has been isolated twice from the same serum in 
this screening but not in any other SEREX screening to date. The synaptonemal complex 
protein 1 (SCP-1) gene was originally identified through SEREX screening of a testis library 
with serum from an RCC patient (Tureci et al 1998).  
 
Restricted expression antigens Restricted expression antigens are those that are expressed in 
only a limited number of tissues, or they may have low level expression in many tissues but 
high expression in a select few. Three of the clones identified in this screening have restricted 
expression. HD-TES-6, 11, and 23 correspond to SECIS binding protein 2 (SBP2), 
Transducin betra like-2 gene (TBL2), and serine/ threonine kinase 33 (STK33), respectively. 
SBP2 has been shown to be overexpressed in testis (Lescure et al 2002). It has been identified 
twice in other SEREX studies. TBL2 is expressed as a 2. 4-kb transcript predominantly in 
testis, skeletal muscle, heart and some endocrine tissues, with a larger approximately 5-kb 
transcript detected ubiquitously at lower levels (Perez et al 1999). TBL2 has not been 
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identified before by SEREX. STK33 is expressed in many but not all tissues (Mujica et al 
2001). In this study, STK33 has been isolated 3 times by two different sera. It has not been 
identified previously by other SEREX studies.  
 
Upregulated antigens The antigens in this category are normally ubiquitously expressed but 
have been found to be upregulated in cancer. Three of the known genes fall into this category. 
HD-TES-2, 18, and 46 correspond to lactate dehydrogenase B (LDHB), Valosin containing 
protein (VCIP), and Retinoblastoma interacting protein 8 (RBBP8), respectively. Lactate 
dehydrogenases are metabolic enzymes which catalyze the conversion of L-lactate to 
pyruvate, the last step in anaerobic glycolysis. Overexpression of LDHB has been found in 
breast cancer cell lines as compared to normal tissues (Forti et al 2002). Serum antibodies 
against LDHB have been identified in four other SEREX studies. VCIP is a member of the 
"ATPases associated with various cellular activities" superfamily and plays a key role in the 
ubiquitin-dependent proteasome degradation pathway (Dai et al 1998). Increased expression 
of VCIP has been found in pancreatic ductal adenocarcinoma, colorectal carcinoma and 
gastric carcinoma and has been shown to correlate with lymph node metastasis and with 
disease progression (Yamamoto et al 2004, 2004, 2003). No other SEREX studies have 
identified VCIP as an antigen before. RBBP8 is a binding partner for the retinoblastoma (RB) 
protein, which is a known tumor suppressor. RBBP8 is expressed ubiquitously at low levels 
and has been found to be upregulated in many tumor cell lines (Fusco et al 1998). RBBP8 
itself has not been identified previously by SEREX but two other family members (Rbbp6 and 
Rbbp7) have. 
 
Normal ubiquitous antigens Antigens in this group are ubiquitously expressed and to date 
have not been shown to be overexpressed in cancer. The greatest proportion of antigens 
identified in this screening belong to this group. This is also the case for most other SEREX 
studies. The majority of entries in the SEREX database belong to normal ubiquitously 
expressed genes. For most of these antigens, seroreactivity is expected to be equivalent in 
both normal controls and cancer patients. Therefore, presence of antibodies against these 
antigens is not related to disease. 
 
Unknown antigens The sequences from all of the unknown antigens were virtually translated 
in all 3 frames to identify possible open reading frames (ORFs). The most likely ORFs were 
then compared to the protein databases using BlastP. Many of the antigens did not contain any 
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significant ORFs and were therefore not studied futher. Three more sequences were found to 
contain ALU repeat sequences. Alu repetitive sequences are interspersed in the human 
genome with an average spacing of 4 kb. Some of them are actively transcribed by pol III. 
Normal transcripts may contain Alu-derived sequences in 5' or 3' untranslated regions. 
However, cDNA libraries also contain partial and/or rearranged cDNAs ligated with Alu-
derived sequence in any orientation. Although Alu elements (especially situated on the 
complementary strand) have a great potential to create additional/alternative exons, 
consideration should be given to the possibility that the presence of an Alu in an open reading 
frame may have resulted from a cloning artifact or may be due to misinterpretation of 
sequencing data. Therefore these clones were not examined any further. Only 8 of the known 
antigens were found to have significant open reading frames which also do not correspond to 
Alu repeat sequences. Table 15 lists the 8 antigens and their homologies to other proteins. 
 
 
Clone 
HD-TES 
Chr. Protein homology Predicted Expression 
(Virtual Northern) 
9 8 No homologies / 1 possible ORF unknown 
10 22q11.2 No homologies / 3 possible ORFs unknown 
28 14q32.32 Hypothetical protein FLJ23027 Low ubiquitous Increased in retina 
and spine 
35 4q12 Hypothetical protein FLJ13621 Highly ubiquitously expressed 
40 4q12 KIAA 0635 protein Low ubiquitous Increased in lung, 
heart and stomach 
44 16p13.3 KIAA 0643 protein Low ubiquitous 
51 17q24.3 Hypothetical protein MGC33887 Low ubiquitous 
58 22q11.23 KIAA0376 protein Low ubiquitous. Increased in 
pancreatic and lung carcinoma 
Table 15. Protein homologies and predicted expression of 8 of the unknown clones 
 
 
Expression of the clones was predicted by virtual Northern. No predictions could be made for 
clones HD-TES-9 and 10. The other clones appear to be expressed ubiquitously at low levels 
with the exception of HD-TES-35 which is predicted to be expressed ubiquitously at high 
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levels. Both HD-TES-40 and 58 are predicted to be upregulated in cancer. HD-TES-40 and 44 
have previously been identified by SEREX but not any of the other unknown clones. 
 
 
3.2.4.2 mRNA expression and seroreactivity of HD-TES-1 to 59 
 
 
The mRNA expression of 23 of the 59 clones was examined by Northern blotting of 24 RCC 
patients (both normal and RCC tissue). Expression of the CT antigens were also examined by 
RT-PCR. For the CT antigens, no signals could be detected on Northern blots nor by RT-
PCR. This could be due to the low level of expression and the low frequency of expression of 
CT antigens. For all other antigens, signals could  be detected on Northern blots. However, no 
differential expression could be detected except in the case of HD-TES-46 (RBBP8) (Figure 
10). It is possible that some of the antigens are post transcriptionally regulated. This would 
not be detected by Northern or RT-PCR. Altered post-translational modifications or mutations 
may also cause induction of antibodies. 
 
 
 
 
 
 
 
 
Figure 10. Expression of HD-TES-46 (RBBP8) in 6 samples of RCC.  
N: Normal kidney tissue. T: Tumor kidney tissue. 
 
N N N N N N T T T T T T 
HD-TES-46/ 
RBBP8 
GAPDH 
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While the loading of mRNA is not equal for all samples (as judged by the GAPDH control), it 
can be clearly seen that RBBP8 is upregulated in the tumor of two of the six patients (First 
and last patients in Figure 10). Analysis of a further 18 patients did not show upregulation of 
RBBP8 in any more RCC patients. 
 
The seroreactivity of 34 of the clones was determined by secondary SEREX with 35 RCC 
sera and 15 sera from healthy controls. The results of this screening are summarized in Table 
16. 
 
The majority of the antigens screened here seem to elicit a similar frequency of antibody 
responses in both normal controls and healthy patients. HD-TES-2, 5, 11, 13, 22, 23, 25, 28, 
31, 32, 35, 37, 39, 42, and 44 all appear to fall into the category of non-cancer related 
autoantigens. The majority of the antigens in this group (10/15) have not been identified 
before by SEREX and thus represent novel autoantigens. 
 
Eight of the antigens elicit antibody responses more frequently in RCC patients than in 
healthy controls. HD-TES-4, 10, 12, 24, 41, 46, 47 and 50 belong to this category. The 
difference between seroreactivity in RCC patients and normal controls varies for each clone. 
The frequency difference ranges from 1.4 (HD-TES-4) to 4.8 (HD-TES-47) times higher in 
cancer patients. Whether the increase in antibody responses is related to cancer is unclear. 
Only 2 of the 8 antigens in this group (HD-TES-4 and 12) have previously been identified 
before by SEREX. 
 
The remaining antigens elicit antibody responses only in cancer patients and not in healthy 
controls. Seroreactivity against the antigens HD-TES-9, 14, 18, 27, 30, 48 and 55 are found at 
frequencies of 3% (1 of 35) to 17% (6 of 35). Interestingly, 4 of the 7 antigens in this category 
belong to the cancer testis classification of antigens. HD-TES-14, 27, 30 and 55 have all been 
described to be expressed only in testis tissue. HD-TES-18, which corresponds to valosin 
containing protein is known to be upregulated in some cancers. The other two antigens are of 
unknown function. Four of the antigens (HD-TES-9, 14, 18 and 30) have not been identified 
by other SEREX screenings 
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Clone 
HD-TES 
RCC serum 
n=35 
Normal serum 
n=15 
Clone 
HD-TES 
RCC serum 
n=35 
Normal serum 
n=15 
2 60% 53% 30 11% 0% 
4 57% 40% 31 20% 27% 
5 23% 27% 32 6% 7% 
6 23% 0% 34 31% 7% 
9 11% 0% 35 26% 20% 
10 46% 27% 37 6% 7% 
11 9% 7% 39 20% 20% 
12 20% 7% 41 20% 7% 
13 11% 13% 42 30% 27% 
14 11% 0% 44 17% 13% 
18 17% 0% 46 40% 13% 
22 34% 27% 47 34% 7% 
23 17% 13% 48 3% 0% 
24 29% 13% 50 40% 20% 
25 14% 7% 55 9% 0% 
27 11% 0% 57 6% 0% 
28 17% 7% 58 31% 20% 
 
Table 16. Seroreactivity of RCC patients versus healthy controls for 34 of the 59 antigens. 
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3.3 SADA 
 
 
SADA (Serum Antibody Detection Array) is based on the SEREX method and is used to 
determine seroreactivity against known antigens. In this method, phages containing the gene 
of interest are spotted at high concentrations on agar plates. Up to 96 different phages can be 
plated on one plate. Once the plaques are transferred to nitrocellulose membranes, the 
procedure is the same as for SEREX. In this study we have analysed the seroreactivity of 
RCC patients versus normal healthy controls for 44 different known antigens. These known 
antigens have been identified in previous SEREX screenings of melanoma and cutaneous T-
cell lymphoma (CTCL) libraries (Stefan Eichmüller: Skin Cancer Unit, DKFZ, Heidelberg). 
Table 17 lists the phages used here. The phages are arranged on the SADA membrane 
according to Figure 11. Figure 11 also shows examples of normal and RCC sera on the SADA 
membranes. 
 
The 44 antigens used here were divided into 2 membranes with each antigen spotted twice on 
each membrane. Screening with each serum was repeated twice and antigens were only 
considered positive if the duplicates were positive on both occasions. A spot was scored as 
positive if it was clearly darker than the spots corresponding to the negative phage. Table 18 
summarizes the results of the SADA screening. Only antigens that showed reactivity with sera 
are shown. 
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Table 17. List of the phages used in the screening of RCC sera by the SADA method 
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 Figure 11. Examples of seroreactivity of normal and RCC sera on the SADA 
membranes.  
N; normal serum. T; RCC serum. 
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                     Table 18. Seroreactivity of RCC patients versus healthy controls. 
                     Antigens not displaying reactivity with either RCC sera or healthy controls are                        
not shown. 
 
 
Reactivity against the above antigens can be divided into 3 categories; 1) antigens to which 
the majority of both healthy and RCC patients are reactive (autoantigens), 2) antigens to 
which RCC patients are more reactive towards, and 3) antigens to which RCC patients are 
exclusively reactive ( i.e. no reactivity in healthy controls).  
 
The GOLGA4 antigen and the Lar interacting protein both fall into the category of 
autoantigens according to this screening. It is already known that the GOLGA4 is an 
autoantigen. The Lar interacting protein, on the other hand, has not been identified before as 
an autoantigen. While it was not the original intention, the presence of these autoantigens on 
the SADA membranes served as a positive control.  
 
No. Clone RCC serum 
n = 35 
Normal serum 
n = 15 
2 Rbbp21a 3% 0% 
4 cTAGE-5a 3% 0% 
5 Par-3ta 23% 0% 
7 RAP140 3% 0% 
11 SCP-1 29% 7% 
13 se57-1 17% 0% 
15 CKAP2 6% 0% 
17 LTA 1-1 37% 20% 
20 GOLGA4 94% 87% 
22 GAGE-3 3% 0% 
32 Lari 1a/b 97% 100% 
33 HEXIM-1 11% 0% 
36 CDA1 26% 7% 
38 ZNF 133 40% 7% 
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Four of the antigens screened fall into the second category. SCP-1, LTA 1-1, CDA1 and ZNF 
133 all show a higher percent reactivity in RCC patients than in normal healthy controls. 
However, the difference between the level of reactivity between healthy controls and RCC 
patients varies e.g. 29% versus 7% for SCP-1, 40% versus 7% for ZNF 133. 
 
The 3rd category contains the most antigens. Seroreactivity against Rbbp21a, cTAGE5a, Par-
3, RAP 140, se57-1, CKAP2, GAGE3, and HEXIM-1 was only found in RCC patients and 
not in healthy controls. This, however does not mean that only RCC patients have antibodies 
against these antigens. Patients with other tumor types are reactive against these antigens ( 
these antigens have previously been identified by SEREX). For some of the antigens, where 
only 3% of patients are reactive (Rbbp21a, cTAGE-5a, RAP140, GAGE-3), the size of the 
groups are too small to make any conclusions. For the other 3 antigens, Par-3, se57-1 and 
HEXIM-1, significant numbers of patients have antibodies against these antigens (23%, 17% 
and 11% respectively). 
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4. Discussion 
 
 
Molecular biological and serological techniques have been used here to identify genes and 
antigens associated with RCC. Through SSH, 2 genes (BACE2 and SUPT5H) could be shown 
to be upregulated in RCC. The frequency of upregulation of 9 other genes and their relation to 
tumor progression was also examined. Through the SEREX method, 74 antigens could be 
identified. These antigens have been examined for their expression profile and seroreactivity 
in RCC patients. Finally, a further 44 antigens have been examined by the SADA method to 
determine seroreactivity in RCC. The relationship of the genes and antigens identified here to 
RCC, the RCC Immunome and cancer in general is discussed below. 
 
 
4.1 Genes identified by SSH 
 
 
The identification of MAGE-9, a cancer/ testis antigen, by SSH in RCC (Pitzer et al 1999) led 
to the further use of this technique in the hope of identifying further RCC associated antigens. 
Screening of a pooled library resulted in the identification of 12 genes with differential 
expression in RCC. Two of these genes (BACE2 and SUPT5H) could be shown to be highly 
upregulated in RCC.  
 
BACE2. Beta-site amyloid precursor protein cleaving enzyme 2 (BACE2) is a glycosylated 
transmembrane protein of the aspartyl protease family (Bennet et al 2000). It is highly 
homologous to BACE1 and both are involved in the processing of amyloid precursor protein 
(APP) to amyloid beta peptide (Ab) (Farzan et al 2000). Cerebral deposition of amyloid beta 
peptide is an early and critical feature of Alzheimer's disease and a frequent complication of 
Down syndrome. Accumulation of Ab  is also found in the muscle of patients with sporadic 
inclusion-body myositis (s-IBM) and hereditary inclusion-body myopathy (h-IBM) (Askanas 
et al 2001). Indeed, BACE2 localizes to the 'Down critical region' of chromosome 21and is 
thus thought to play a major role in the progression of this disease. Montanaga et al (2002) 
have detected increased expression of BACE2 in the brains of Down syndrome patients 
displaying alzheimer neuropathology but not in brains without alzheimer neuropathology. 
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BACE2 mRNA is expressed at low levels in most human peripheral tissues and a higher 
levels in colon, kidney, pancreas, placenta, prostate and stomach. Increased expression has 
been found in breast cancer and BACE2 is suggested to contribute to the proteolytic cascade 
in neoplastic cells (Xin et al 2000). Also worth noting is the fact that APP, the target of 
BACE2, is involved in the growth of human colon carcinoma cells in vitro and in vivo (Meng 
et al 2001). 
 
In this study, BACE2 was found to be upregulated in 10 out of 22 RCC patients tested (45%). 
It was also found to be highly expressed in 5 of 10 RCC cell lines and 9 of 22 lung carcinoma 
cell lines. Statistical analysis showed a preferential expression in mixed and oxyphil RCC. 
BACE2, therefore, seems to play a significant role in RCC and other cancers. Targeting 
BACE2 with specific inhibitors (as suggested for the treatment of Alzheimers) may be of 
benefit in controlling tumor growth and progression.  
 
BACE2 does not appear to be immunogenic. Loading of dendritic cells with BACE2 derived 
peptides did not induce proliferation of T cells in a mixed lymphocyte reaction. Also, no 
antibodies could be detected in RCC patients against BACE2 in a secondary serex screening 
of this molecule. 
 
SUPT5H. SUPT5H is the human homolog of the yeast gene SPT5 (Suppressor of Ty 5). The 
SPT genes were identified through a genetic screening for mutations in the yeast 
Saccharomyces cerevisiae that restore gene expression disrupted by the insertion of the 
transposon Ty. SUPT5H is mapped to chromosome 19q13 and encodes a 1087aa protein that 
is expressed in all tissues. Together with SUPT4H and SUPT6H, SUPT5H is known to play a 
critical role in transcription elongation and activation of transcription (Wen and Shatkin 1999, 
Kaplan et al 2000, Yamaguchi et al 2001). 
 
Overexpression of SUPT5H has not been shown before for any cancer. In this study it was 
shown to be overexpressed in 17 of 31 RCC patients (55%). It was mainly seen in clear cell 
RCC. As SUPT5H is critical for transcription initiation and elongation, it is not surprising that 
this gene is upregulated. Upregulation of this gene in cancer probably enhances cell 
proliferation. However, this also makes SUPT5H an unlikely target for immunotherapy as to 
interfere with this molecule would be lethal for both normal and cancer tissue. 
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4.1.1 Expression of previously identified SSH genes in RCC 
 
 
The expression of 9 other genes in 35 RCC patients, previously identified by SSH, was 
examined in order to determine if there is a correlation between upregulation of the gene and 
tumor histology, grading or staging. All of the genes examined here have some relation to the 
tumorigenic process. Three of the genes, (Cyclin D1 C1-RC and IGFBP3) are related to tumor 
growth/ survival. Three more are related to angiogenesis (VEGF, CP and ARP-2). The final 
three are involved in cell adhesion/ motility (ATX, LO, SemG). The overexpression of these 
genes in RCC is therefore no surprise. The fact that some of these genes are overexpressed in 
80-90% of RCC suggests that they are important for tumor progression. Although no 
correlation could be made between gene upregulation and grading, overexpression of 6 of the 
genes (VEGF, ARP2, ATX, LO and SemG) was found mainly in clear cell RCC. The 
overexpression of ATX and LO was found to correlate with tumor progression. Whether this 
is of prognostic relevance remains to be seen pending the outcome of a follow-up study. As 
the overexpression of these genes is clearly important for tumor progression, direct inhibition 
of these gene products may therefore help in controlling the growth of the tumor. Thus, the 
genes examined here are potential therapeutic targets. 
 
 
4.2 Antigens identified by SEREX 
 
 
Genes identified by the SEREX method are by definition antigens, as they have elicited an 
antibody response which is thought to reflect T cell help. In this study, 3 cDNA libraries 
(RCC tumor, RCC cell line and Testis) have been screened with serum from RCC patients in 
an attempt to elucidate, at least in part, the RCC Immunome. 74 antigens have been identified 
in total which can be grouped according to the following antigen categories: Cancer/Testis, 
Restricted expression, Upregulated antigens, Translocation antigens, Normal/autoantigens and 
Unknown antigens. 
 
 
Cancer/Testis antigens Cancer/Testis antigens are considered to be ideal candidates for 
immunotherapy due to their restricted expression. In this study 6 CT antigens have been 
Discussion  - 93 – 
 
identified. The six antigens (RANBP2L1, TSGA10, PLU-1, STK31, BRDT and SCP-1) have 
been examined for their mRNA expression and seroreactivity in RCC. 
 
RANBP2L1 is identical on its 5’ end to RANBP2 and is thought to have resulted from a 
duplication of the RANBP2 gene. RANBP2 is a large 358-kDa protein which is localized at 
the cytoplasmic side of the nuclear pore complex and likely constitutes the RAN-GTP binding 
site at the cytoplasmic face of the complex (Melchior et al 1995). RANBP2L1 is a testis-
specific nucleoporin and possibly acts as a docking site and a cotransporter of Ran and 
transportin (Cai et al 2002). It has not been associated before with cancer and unfortunately 
expression of this gene could not be confirmed in RCC patients. There does however seem to 
be an increase in seroreactivity in RCC patients as compared to healthy controls (57% and 
40% respectively). The question remains however, whether the antibody against RANBP2L1 
is specific or whether it is a crossreacting antibody which reacts with the highly related 
RANBP2. Indeed, RANBP2 itself was also isolated in this study. Experiments to prove the 
specificity of the anti-RANBP2L1 antibody would need to be conducted to confirm this genes 
role as an RCC antigen. 
 
TSGA10 is predicted to play a role in the sperm tail fibrous sheath (Modarressi et al 2004). 
TSGA10 mRNA transcripts could not be detected in RCC patients. It may be that it is 
expressed at a very low level in tumors and thus difficult to detect. It is also likely to be 
expressed at a low frequency. Many CT antigens are expressed at frequencies between 5 and 
20%. Indeed the seroreactivity against TSGA10 in RCC patients reflects this (11%). Healthy 
controls did not possess antibodies against this gene. This makes TSGA10 a possible 
candidate as a diagnostic or prognostic marker. 
 
PLU-1 is a large nuclear protein that is proposed to function as a regulator of gene expression 
and interacts with the developmental transcription factors BF-1 and PAX9 (Tan et al 2003). 
Barret et al (2002) have shown that PLU-1 is expressed at high levels in testis but not any 
other human adult tissue except for ovaries. They also found PLU-1 to be upregulated in 
breast cancer. Again mRNA for this gene was not detectable in RCC patients but the 
seroreactivity profile was similar to that of TSGA10 and other CT antigens (11%). Presence 
of anti-PLU-1 antibodies in serum is thus a potential marker for cancer. 
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STK31 has only been identified recently in a systematic search for genes expressed in mouse 
spermatogonia but not in somatic tissues (Wang et al 2001). Nothing is known about this 
protein to date except that it is expressed only in testis tissue. Like the other CT antigens 
identified here, mRNA expression from this gene could not be confirmed. The restricted 
seroreactivity (11% of patients) makes this another potential candidate as a diagnostic or 
prognostic marker for RCC. 
 
BRDT is a testis-restricted member of the RING3 protein family (Jones et al 1997). It 
possesses 2 bromodomain motifs and a PEST sequence (a cluster of proline, glutamic acid, 
serine and threonine residues), characteristic of proteins that undergo rapid cellular 
degradation. The bromodomain is found in proteins that regulate transcription. BRDT has 
been shown to play a role in the large-scale reorganization of acetylated chromatin (Pivot-
Pajot et al 2003). Expression of BRDT was found in 12 of 47 cases of non-small sell lung 
cancer (Scanlan et al 2000). It has not been found previously in RCC. BRDT expression could 
not be confirmed in this study by RTPCR or Northern blotting. There was no significant 
difference in seroreactivity between RCC patients and healthy controls (20% versus 27%). 
BRDT is thus not a good candidate as a potential prognostic, diagnostic or therapeutic target. 
 
As well as RCC, SCP-1 has been found to be expressed in melanoma, breast cancer, 
cutaneous T-cell lymphoma, stomach cancer and hepatocellular carcinoma (Tureci et al 1998, 
Eichmüller et al 2002, Jager et al 2002, Eichmüller et al 2001, Mashino et al 2001, Chen et al 
2001). SCP-1 is expressed during the meiotic prophase of spermatocytes and is involved in 
the pairing of homologous chromosomes (Tureci et al 1998). In this study 9% of RCC 
patients were found to have antibodies against SCP-1. This would be consistent with the 
expression pattern found by Tureci et al (1998) of 3 out of 36 RCC patients. Unfortunately 
this could not be confirmed for the RCC patients used here. The expression of SCP-1 and the 
presence of antibodies against it seem to be strongly associated with cancer. SCP-1 is 
therefore a strong candidate as an immunotherapeutic target, not only on RCC but also many 
other cancers. 
 
 
Restricted expression antigens Antigens showing restricted expression may not be suitable 
candidates for immunotherapy but their overexpression in a tumor may serve as diagnostic or 
prognostic markers. Three antigens (SBP2, TBL2, STK33) with restricted expression were 
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identified in this study. Their expression in RCC and the frequency of antibody responses 
against each of these antigens was examined. 
 
SBP2 is one of the key players in the synthesis of selenocysteine and selenoproteins. 
Selenoproteins are normally enzymes with selenium in the form of selenocysteine at their 
active site. Most of these enzymes are involved in redox reactions. Thioredoxin reductase and 
glutathione peroxidase are just two examples. Another example is the phospholipid 
hydroperoxide glutathione peroxidase which is involved in sperm maturation (Ursini et al 
1999). It is therefore no surprise to find SBP2 highly expressed in testis tissue. What role 
SBP2 might play in cancer, if any, is unclear. There was no differential expression of SBP2 
between normal and tumor kidney for 24 RCC patients. However, 23% of patients have 
generated an antibody response against this protein in comparison to 0% of controls. The 
induction of anti-SBP2 antibodies must therefore be related to the tumorigenic process. 
Whether this is specific for RCC remains to be seen. 
 
TBL2 is a member of the transducin family which have regulatory functions. TBL2 encodes a 
protein with four putative WD40-repeats. WD40 domains are found in a number of eukaryotic 
proteins that cover a wide variety of functions including adaptor/regulatory modules in signal 
transduction, pre-mRNA processing and cytoskeleton assembly. TBL2 has been shown to be 
deleted in Williams-Beuren syndrome (WBS), which is a developmental disorder (Perez et al 
1999). There is no known association of TBL2 with cancer. In this study, mRNA levels were 
similar in both normal and tumor kidney. Also, seroreactivity was similar in both RCC 
patients and healthy controls (9% versus 7%, respectively).TBL2 is therefore not suitable as a 
diagnostic or prognostic marker. 
 
STK33 belongs to the family of serine/ threonine kinasess. Protein kinases represent a large 
diverse family which play major roles in signal transduction, DNA replication, metabolic 
pathways and cell growth, differentiation, proliferation and cell death (Hanks and Hunter 
1995, Wilmanns et al 2000). Very little is known so far about STK33 apart from its’ 
chromosomal location. It is localized to chromosomal region 11p15 which is known to be 
associated with several diseases including predispositions to develop various tumor types 
Bepler and Koehler 1995, Redeker et al 1995). STK33 may belong to the calcium/calmodulin-
dependent protein kinase group. If expression of STK33 itself predisposes to certain cancers 
is not known. It was not found to be differentially expressed in RCC patients. Neither was 
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there a significant difference in seroreactivity between RCC patients and controls (175 versus 
13%, respectively). STK33 is therefore also not suitable as a diagnostic or prognostic marker. 
 
 
Upregulated antigens Ubiquitously expressed genes that are upregulated in cancer often lead 
to the induction of an antibody response and many such antigens have been identified by 
SEREX. The identification of upregulated gene products can also give insight into the 
tumorigenic process. While upregulation of some genes may only be a result of increased 
proliferation, the upregulation of other genes may confer a distinct growth advantage for 
proliferating cells. As discussed earlier, most of the SSH identified genes that were screened 
here are related to tumour growth/survival, angiogenesis, and cell adhesion/motility. Four 
antigens (LDHB, VCIP, RBBP8and MnSOD) were identified that have previously been 
shown to be upregulated in other cancers. All four have been checked for their mRNA 
expression and seroreactivity in RCC. 
 
Lactate dehydrogenases are metabolic enzymes which catalyze the conversion of L-lactate to 
pyruvate, the last step in anaerobic glycolysis. Malignant cells tend to use 5-10 fold more 
glucose than do normal tissues, deriving energy for active proliferation mainly from anaerobic 
glycolysis. Although It is not clear whether the increased serum levels of LDHs commonly 
found in cancer patients reflect greater production and release of the enzymes by malignant 
cells, it is well known that increased serum LDH activity has diagnostic and prognostic 
significance in patients with various tumors (Dumontet et al 1999, Buamah et al 1990, Finck 
et al 1983). Levels of LDH were found not to differ in the 24 RCC patients examined here. 
There was no significant difference in the seroreactivity of RCC patients and healthy controls 
to the LDHB antigen. Thus, at least for RCC, LDH is not a suitable marker or therapeutic 
target. 
 
VCIP is a member of the "ATPases associated with various cellular activities" superfamily 
and plays a key role in the ubiquitin-dependent proteasome degradation pathway (Dai et al 
1998). VCIP is known to inhibit apoptosis after stimulation with cytokines such as tumor 
necrosis factor via degradation of inhibitor B , an inhibitor of nuclear factor- B (Dai et al 
1998). Although it is found to be upregulated in other cancers, it could not be confirmed here 
in this study for RCC. However, 17% of RCC patients had antibodies against the VCIP 
protein in contrast to 0% of controls. The presence of anti-VCIP antibodies in serum may 
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therefore be a marker cancer. Whether this is specific for RCC or whether it has prognostic 
significance remains to be seen. 
 
The retinoblastoma binding protein 8 (RBBP8) is localized on chromosome 18q11.2. Very 
little is known about this gene apart from the fact that it can bind to the retinoblastoma (RB) 
protein (Fusco et al 1998). The RB protein is a nuclear polypeptide that is phosporylated in a 
cell cycle-dependent manner (Taya, 1997). Unphosphorylated RB represents the active form, 
which binds other nuclear proteins, including the E2F transcription factor (Bandara and La 
Thangue 1991, Chellappan et al 1991). The RB-E2F complex leads to repression of 
transcription (Adnane et al 1995). Phosphorylation or sequestration of RB by other proteins 
releases E2F, which is then able to activate transcription (Buchkovich et al 1989, Bandara and 
La Thangue 1991). Molecular alterations of the Rb gene are infrequent (<2%) in renal 
cancers, and Rb protein is present in the majority of primary (92%) and metastatic (100%) 
renal tumors (Presti et al 1996). The interaction of RBBP8 with RB may allow transcription 
of genes that promote cell proliferation. It is no surprise to see that RBBP8 is overexpressed 
in many tumor lines (Fusco et al 1998). In this study, RBBP8 was found to be upregulated in 
2 of 24 RCC patients. It was also found to be highly expressed in 4 RCC cell lines. The 
seroreactivity profile also suggests a strong correlation with cancer. 40% of RCC patients 
have antibodies against RBBP8 whereas only 13% of healthy controls react to this protein. 
This is the first demonstration of the upregulation of a retinoblastoma binding protein in RCC. 
The upregulation of RBBP8 and the presence of anti-RBBP8 may be of diagnostic or 
prognostic significance. 
 
Both upregulation and downregulation of MnSOD have been demonstrated in different 
cancers. The differences are thought to depend on the cell type. In this study the mRNA 
expression level of MnSOD was found to be equivalent in both normal kidney and RCC 
tissue. However, seroreactivity against MnSOD was found to be differential between healthy 
controls and RCC patients. 14% of RCC patients were found to have anti-MnSOD antibodies 
in contrast to 0% of controls. An increase in anti-MnSOD antibodies was also found by 
Unwin et al (2003) in their SERPA analysis of RCC. Presence of Anti-MnSOD antibodies 
may therefore be of diagnostic or prognostic significance for RCC. 
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Translocation antigens Both development and progression of cancer are associated with 
nonrandom chromosomal abnormalities (Wada et al 1997). Several cytogenetic studies 
describe correlations between various cytological subtypes or RCC and specific chromosomal 
aberrations (Zhao et al 1995, van den Berg et al 1993 van der Hout et al 1993). Loss of 
chromosome 3p or translocations between 3p13 and 5q22 are frequent in RCC (Kovacs G 
1993). The VHL gene, which is mutated in 57% of sporadic RCC, is located on 3p25-26. The 
VHL gene is also associated with hereditary RCC (Gnarra et al 1995). A translocation 
between chromosome 19 and 12p12 has been identified here in this study. Such a 
translocation has not been identified before for RCC. However, gains of chromosomes 12 and 
19 have been shown for RCC (Zhao et al 1995, van den Berg et al 1993 van der Hout et al 
1993). It is likely to have been a unique event, occurring only in 1 of 35 patients. The 
seroreactivity also reflects this. Only this patient had antibodies against the phage produced 
protein. This antigen is therefore not useful for diagnostic or prognostic purposes. 
 
 
Normal autoantigens Approximately 50% of the antigens identified in this study can be 
considered to be normal ubiquitously expressed autoantigens. This is also the case for most 
other SEREX studies, as demonstrated by the sheer number of such antigens in the SEREX 
database. The majority of these autoantigens elicit antibodies at a similar rate in both healthy 
controls and cancer patients. Increased seroreactivity was found in this study for 4 supposedly 
normal autoantigens. Expression analysis found no difference in mRNA levels for each of the 
4 antigens between controls and RCC patients. Four of the antigens (HD-TES-34/ SEC63, 41/ 
CENPE, 47/ Yipee, 50/ SBNO1) were found during the screening of the testis library.  
 
SEC63-like is the human homolog of the yeast Sec63 gene (Sec63). In yeast, the Sec63 
protein (Sec63p) forms a complex with Sec61p, Sec62p, Sec71p and Sec 72p which together 
form the Sec complex (Deshaies and Schekman 1987, Hartmann et al 1994, Deshaies et al 
1991). This complex is essential and sufficient for the post translational protein translocation 
into the endoplasmatic reticulum (ER) (Panzner et al 1995). Although it does not appear to be 
upregulated in RCC, 31% of RCC patients have antibodies against the SEC63-like protein. 
For comparison, only 7% of healthy controls have anti-SEC63-like antibodies. Presence of 
these antibodies may therefore be an indicator of disease progression. 
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The kinetochore-associated microtubule motor protein CENP-E (centromere associated 
protein-E) is required for establishing and maintaining the mitotic checkpoint, the major cell 
cycle control pathway in which unattached kinetochores prevent anaphase onset (Abrieu et al 
2000). This checkpoint is essential for accurate seperation of chromosomes during mitosis. 
CENP-E has been shown to interact with other kinetochore proteins such as CENP-F. 
Antibodies against CENP-F have also been identified in this study aswell as many other 
SEREX studies. However, anti-CENP-F antibodies have been found at similar frequencies in 
both cancer patients and healthy controls in all of these studies. Anti-CENP-E antibodies have 
not been identified by SEREX but have been found to be associated with a particular form of 
systemic sclerosis (SSc) (Rattner et al 1996). In this study 20% of RCC patients had 
antibodies against CENP-E compared to 7% of controls. As CENP-E is important for cell 
division, the increase in autoantibodies against CENP-E could reflect the increased 
proliferation of RCC cells. Alternatively, mutations in CENP-E, which may result in 
chromosomal aberrations, could be the trigger for these autoantibodies. 
 
The Yippee protein has only been identified recently in a yeast interaction trap screen for 
interactions with Hyalophora cecropia Hemolin (Roxstom-Lindquist and Faye 2001). 
Hemolin is a member of the immunoglobulin superfamily which is constitutively expressed 
and strongly upregulated upon bacterial infection (Andersson and Steiner 1987, Lindstrom-
Dinnetz et al 1995). It is the first member of a new  family of proteins highly conserved 
among eukaryotes. Yippee appears to be a ubiquitous intracellular protein with a potential to 
bind zinc and a capacity to interact with itself. In this study, expression levels of Yippee were 
found to be the same for normal kidney and RCC tissue. However there was a large difference 
in seroreactivity between healthy controls and RCC patients (7% versus 34% respectively). 
As there is so little known about this protein, to speculate on its role in cancer would be 
unwise.  
 
The strawberry notch homolog-1 (SBNO1) gene is the human equivalent of the strawberry 
notch gene originally identified in Drosophila. It participates with members of the Notch 
pathway in facilitating developmentally relevant cell-cell communications (Coyle-Thompson 
and Banerjee 1993). Analysis by virtual northern shows that it is expressed in many normal 
tissues. In this study, equivalent amounts of SBNO1 were found in both normal kidney and 
tumor tissue. However, antibodies against SBNO1 are twice as frequent in RCC patients as 
healthy controls (40% versus 20%). No association with cancer has been identified todate for 
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SBNO1. However, many developmentally associated proteins are found to be associated with 
cancer. Whether SBNO1 can be considered a true developmental gene is unclear. 
 
 
Unknown antigens In total, 22 unkown antigens have been identified in this study. However, 
only 12 of these were found to contain significant ORFs that do not correspond to ALU repeat 
sequences. Of these 12, 10 are predicted to be expressed ubiquitously. The expression of the 
other two (HD-TES-9, 10) could not be predicted. Subsequent analysis by northern blotting 
showed equivalent levels of these two genes in both normal kidney and RCC tissue. Three of 
the 12 antigens (HD-RCC-1, 2, 3) elicited antibodies in only 1 patient out of 35 and not in 
healthy controls. These antigens are therefore patient specific and not suitable as diagnostic, 
prognostic or therapeutic targets. Of the remaining 9 antigens only 3 (HD-TES-9, 10, 24) 
displayed differential seroreactivity between RCC patients and healthy controls (11% versus 
0%, 46% versus 27%, 29% versus 13%, respectively). The role of these 3 antigens in cancer 
cannot be speculated. However, upregulation at the mRNA level can be ruled out. 
 
 
4.3 RCC associated antigens identified by SADA 
 
 
The SADA (serum antibody detection array) technique is an extension of the SEREX method. 
It is used for determining the frequency of antibody responses in patients against many known 
antigens simultaneously. In this study 44 previously identified antigens were studied for their 
seroreactivity in 35 RCC patients versus 15 healthy controls. Of the 44 antigens only 14 
displayed seroreactivity in RCC patients. Eight of the antigens were found to exclusively react 
with RCC sera and not healthy controls. Four other clones displayed increased seroreactivity 
in RCC patients as compared to controls. The last two antigens displayed almost 100% 
seroreactivity in both RCC patients and healthy controls. Of the eight antigens showing 
exclusive seroreactivity in RCC patients, four (Rbbp21a, cTAGE-5a, RAP140, CKAP2, 
GAGE) showed seroreactivity in only 1-2 patients. Interestingly two of these antigens 
(cTAGE-5a and GAGE) are cancer/ testis antigens. The other three in this group (Par-3, se57-
1 and HEXIM1) are discussed in more detail below. The antigens showing increased levels of 
seroreactivity (SCP-1, LTA1-1, SREB-3, ZNF133) are also discussed briefly. 
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The Par-3 gene belongs to the family of partitioning-defective genes which are involved in 
asymmetric cell division and polarized growth. Studies in Caenorhabditis elegans have 
demonstrated the essential role of these proteins in the establishment of anterior/ posterior 
polarity (Nelson and Grindstaff 1997). Par-3 encodes a large protein with three PDZ (PSD-
95/Dlg/ZO-1) domains (Etemad-Moghadam et al 1995). These domains mediate protein–
protein interactions, usually with other PDZ domains or with specific carboxy-terminal motifs 
(Fanning and Anderson 1996, Ponting et al 1997). PAR-3 localizes to the cell periphery at the 
anterior end of the zygote. An atypical PKC, PKC-3, co-localizes with PAR-3 and is also 
required for asymmetric cell division (Tabuse et al 1998), and another par gene product, PAR-
6, which contains a single PDZ domain, co-localizes with PAR-3 and with PKC-3 (Hung and 
Kemphue 1999). The clone used here (Par-3ta) is lacking the first of the three PDZ domains. 
Par-3 is known to be expressed as different splicing products. In normal tissue, 3 splicing 
products have been identified whereas in tumor tissue only one intense band is seen (Usener 
2000). The Par-3ta clone thus appears to be a tumor specific splice variant of the Par-3 gene. 
Usener (2000) also found that this variant is serologically specific for tumor patients. In this 
study 23% of RCC patients were reactive to this clone. It remains to be seen if the apparent 
tumor specific transcript is also present in RCC. 
 
The se57-1 clone was identified in the screening of cutaneous T cell lymphoma (CTCL) by 
SEREX (Eichmüller et al 2001). Its expression was found in normal tissues to be limited to 
bone marrow, colon, small intestine, spleen, testis and trachea. In CTCL it was found to be 
expressed in 6% of patients while seroreactivity was found to be at 33%. Nothing else is 
known about this gene. In this study 17%of patients were found to have antibodies against the 
corresponding protein. No healthy controls were seroreactive for se57-1. The expression of 
se57-1 could not be confirmed in those patients which were reactive. It is thought that the 
se57-1 gene is expressed only at a very low level. This may explain the inability to confirm its 
expression in RCC patients.  
 
The HEXIM1 (Hexamethylene-bis-acetamide-inducible-1) gene was originally identified by 
differential display of vascular smooth muscle cells (VSMC) after treatment with 
hexamethylene-bis-acetamide (HMBA) (Kusuhara et al 1999). It was found to play an 
inhibitory role in NF-kB-dependent gene expression in VSMC (Ouchida et al 2003). Two 
SEREX studies have identified HEXIM1 as an antigen. Seroreactivity in both cases was 
limited to cancer patients (Ehlken et al 2004, Stone et al 2003). Here it was found to elicit 
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antibody responses in 11% of RCC patients but not in any of the controls. The presence of 
anti-HEXIM1 antibodies therefore appears to be a marker cancer in general. 
 
The SCP-1 gene has already been discussed, however it is worth noting that the seroreactivity 
here differs from that obtained earlier with the testis identified clone (HD-TES-55). 
Secondary serex analysis with the HD-TES-55 clone showed 9% seroreactivity against this 
clone in RCC patients only. The SADA analysis on the other hand indicates that 29% of 
patients have antibodies against the SCP-1 protein along with 7% of controls. It may be 
possible that in this case the SADA approach was more sensitive in detecting anti-SCP-1 
antibodies than the secondary serex. Nevertheless, seroreactivity against SCP-1 remains an 
apparent marker for cancer. 
 
LTA1-1 is a ubiquitously expressed peripheral membrane protein localized to the trans-Golgi 
network. The encoded protein contains a GRIP domain which is thought to be used in 
targeting (Luke et al 2003). Previous SEREX analysis has shown that 50% of CTCL patients 
and 0% of healthy controls are reactive against this protein (Eichmüller et al 2001). In this 
study, 37% of RCC patients were seroreactive in comparison to 20% of controls. The 
discrepancy between the two studies with regard to seroreactivity in healthy controls could lie 
in the fact that only 5 controls were taken in the study of CTCL. It may also lie in the 
sensitivity of the SADA method. However, increases in anti-LTA1-1 antibodies may be a 
marker for cancer. 
 
The cell division autoantigen 1 (CDA1) gene was identified in a screening of a testis library 
with serum from a patient with discoid lupus erythematosus (Chai et al 2001). It was found to 
be localized to the nucleus. It is proposed to be a negative regulator of cell growth whose 
activity is regulated by its expression and phosphorylation. Eichmüller et al have found anti-
CDA1 antibodies in 30% of CTCL patients and not in controls. In this study, 26% of RCC 
patients displayed seroreactivity against CDA1 in contrast to only 7% of controls. Presence of 
anti-CDA1 antibodies seems therefore to correlate strongly with cancer. 
 
The ZNF133 gene belongs to the zinc finger Krüppel family (Tommerup and Vissing 1995). 
Zinc finger proteins are important transcriptional activators and repressors. Several 
observations have implicated ZNF genes with developmental and malignant disorders. For 
example, mutations of the zinc finger gene WT1 predispose to the development of Wilms 
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tumor (Call et al 1990) as well as to congenital malformations of the urogenital tract (Pelletier 
et al 1991). The ZNF133 gene was found to be amplified in a neuroblastoma cell line 
(Heiskanen et al 2000). A large number of zinc finger proteins have been identified by 
SEREX. In this study 40% of RCC patients were reactive against the ZNF133 protein 
compared with only 7% of controls. It seems as if seroreactivity to zinc finger proteins is also 
associated with cancer. 
 
 
4.4 Review of the methods used in this study 
 
 
The SSH technique is a powerful method for the identification of upregulated genes. One 
particular advantage over cDNA array is that it can identify unknown genes. However, there 
are some inherent drawbacks with this method. A false positive rate of up to 50% can be 
expected, possibly due to inefficient hybridisation during the subtraction process. It is 
essential to test all clones by northern blotting to confirm differential expression. When the 
goal is to identify antigens, then SSH is not a very suitable technique as shown by this study. 
Also only short transcripts are produced which are unsuitable for expression cloning.  
 
SEREX, on the other hand is ideally suited for antigen identification. For a successful 
screening, a number of crucial steps need to be performed. Firstly, to eliminate antibodies in 
human sera which react with bacterial or phage components, extensive preabsorption of 
diluted serum is essential. When the cDNA library is derived from a tumor which may 
harbour B cells, it is essential either to eliminate IgG clones or to retest all identified clones 
without the test sera (i.e. only with secondary antibody). To determine the relevance of 
identified clones to cancer, the initial step is to sequence the clone and compare this to what is 
in the database. The next step is to determine if the gene has a restricted or non-restricted 
expression in normal tissues and in the tumor being investigated. This is achieved by RTPCR 
or Northern blotting. Finally it is important to determine whether the seroreactivity against the 
identified clone relates to cancer or is non-specific. On a small scale this can be achieved by 
secondary SEREX. This is where the clone is plated at a ~50:50 ratio with empty phage. The 
membrane can then be cut up and used to examine multiple sera. On a larger scale, the SADA 
technique is more suitable, especially if multiple clones are to be analyzed. Alternatively, 
purified recombinant protein can be used in an ELISA. This eliminates the need for 
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preabsorption of sera. It also eliminates the grey area of trying to distinguish between a 
weakly positive signal and a high background which is often arbitrary if not impossible. 
 
A number of modifications to the SEREX method have been established in order to enhance 
its effectiveness. The screening of testis libraries instead of tumor libraries enhances the 
likelihood of identifying cancer/ testis antigens. Another modification is the use of subtracted 
libraries. Clones identified in this manner are much more likely to be differentially expressed 
in the target tumor. One modification that has been proposed is to use different sources of 
antibody. Instead of using autologous or allogenic sera, human oligoclonal or mAb generated 
from B cells from peripheral blood, tumor, or draining lymph nodes of cancer patients could 
be used.  
 
One of the main shortcomings of SEREX is that it is a prokaryotic system. Therefore, 
posttranslational modifications such as glycosylation, lipidation, phosphorylation, 
methylation, etc, are not represented. Folding of proteins is also different in prokaryotes and 
eukaryotes. Such modifications generate confirmational epitopes which are missed by 
conventional SEREX. Recently, Mischo et al (2003) have developed a yeast based system to 
circumvent these problems. 
 
In comparison with other SEREX studies, this study is no exception. The vast majority of 
clones identified are ubiquitously expressed genes that do not show differential expression in 
the tumor. The lack of clones identified in the screening of the tumor library and the RCC cell 
line was however surprising. In the case of the tumor, it may be that this patient’s tumor is not 
very immunogenic. The high dilution (1:3000) of the pooled sera may be also to blame. This 
is also the case for the initial screening of the cell line. However, this also means that the 
clones identified have elicited very high titer antibodies. Indeed, three of the clones represent 
known autoantigens (GOLGA4, UACA and DEK). Two of these autoantigens elicit 
antibodies in the vast majority of both normal and cancer patients. The effective dilution of 
specific antibody would then only be 1:100. In the case of the SNX6 clone, only one patient 
had reactive antibodies. This clone was identified repeatedly in the screening of the cell line 
library and also the testis library indicating a very high titer of anti-SNX6 antibodies in this 
particular patient. However there was no differential expression of SNX6 between the normal 
kidney and the tumor from this patient. Perhaps, SNX6 is posttranslationally upregulated or 
alternatively modified in this patient. 
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The screening of the testis library initially with each individual sera, followed by the top 3 
responding sera allowed for the identification of a significant number of antigens. As well as 
the known ubiquitously expressed genes, a significant number of unknown genes were 
identified. A decent number of upregulated and cancer/ testis antigens were also identified. It 
was however disappointing not to be able to confirm the expression of the cancer/ testis 
antigens in RCC patients. This may be due to the infrequency and low expression level of 
these antigens. However, this should be repeated before making any final conclusions. 
 
As mentioned earlier, one of the drawbacks of the SADA method is trying to distinguish high 
background from weakly positive signals. This may explain some of the discrepancies 
between equivalent clones screened by both secondary SEREX and SADA. The use of the 
GOLGA4 and/ or the UACA autoantigens as positive controls may help to alleviate some of 
these problems and is therefore put forward by this work as a recommendation for future 
SADA studies. Still, the SADA method was found in general to be less sensitive than 
secondary SEREX. Of the 44 antigens screened by SADA, only 14 showed any reactivity in 
either normal or RCC patients. In comparison, all of the clones identified in the testis screen 
were found to be reactive in at least one person when examined by secondary SEREX. 
However, this lack of sensitivity may also be an advantage for identifying cancer related 
clones. Indeed, 57% of clones that were reactive in the SADA screening were shown to react 
exclusively with RCC sera. This compares with 26% of the clones reactive in the secondary 
SEREX screening.  
 
 
4.5 The RCC Immunome 
 
 
The cancer immunome refers to the complete repetoire of immunogenic products in human 
cancer. The goals being 1) to understand better the generation of immune reactions against 
cancer and 2) to identify potential targets for diagnostic, prognostic or therapeutic use. These 
goals are now more acheivable thanks to the SEREX method. While the identification of 
cancer specific antigens is of utmost importance, the identification of antibodies that are 
equally present in both cancer patients and healthy controls as well as antibodies that are more 
frequently found in cancer patients should not be neglected.  
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Natural autoantibodies (na-Ab) were first suggested to have a ‘sewage’ role whereby na-Ab 
are responsible for inactivating any biologically active molecules that are overproduced 
(Grabar, 1975). Since then na-Ab have been shown to have a variety of functions. Some na-
Ab provide transportation of molecules-ligands as well as protection of ligands from 
proteolysis (Wang et al 1992). The finding that some antibodies can modulate functions of 
intranuclear proteins in vivo, suggests that antibodies are also capable of translocation across 
cell membranes (Zaitchik and Churilov, 2001). Antibodies have also been shown to possess 
enzymatic activity (abzymes) (Poletaev and Morozov, 2000). 
 
The fact that autoantibodies do not automatically result in autoimmune disease suggests that 
the source of antigen is less important than the context in which it is presented. This 
observation has led to the concept of the ‘danger’ model which supersedes the previous ‘self/ 
nonself’ model (Matzinger 1994, Fuchs and Matzinger 1996). In this model, any antigen can 
potentially be seen as ‘dangerous’ and stimulate an immune response with the appropriate 
stimuli. These appropriate stimuli are thought to come from proinflammatory cytokines and 
chemokines elaborated by cells of the innate immune system such as naural killer (NK) cells 
and dendritic cells (DC). 
 
Recent work by Nishikawa et al (2001, 2003) using SEREX defined autoantigens, suggests a 
role for these autoantigens in maintaining and regulating immunological homeostasis and that 
this is achieved via CD4+ CD25+ regulatory T cells. Specifically, they found that 
coimmunization of mice bearing a tumor with DNA from a SEREX defined autoantigen plus 
DNA from a tumor-specific CTL epitope leads to heightened CD8+ T cell responses and 
increased resistance to tumor challenge in a CD4+ dependent manner. They also found that 
immunization with DNA from the SEREX autoantigen alone leads to heightened sensitivity to 
tumor challenge and that this was mediated by CD4+ CD25+ regulatory T cells. 
 
The term Immunculus (immunological homunculus) has been proposed recently by Poletaev 
and Osipenko (2003) to describe the network of constitutively expressed na-Ab. They suggest 
that the Immunculus mirrors the organism’s physiological state. In healthy people the 
Immunculus is relatively constant and is characterized by minimal individual quantitative 
variations. However, abnormal metabolic deviations, which precede or accompany different 
diseases result in quantitative rather than qualtitative changes in this network of na-Ab. The 
mapping of this network in healthy individuals should identify the normal state of na-Ab in 
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the healthy condition. Quantitative differences to this norm may then be used for the early 
detection of potentially pathogenic metabolic changes. 
 
Concerning this work, the majority of the antigens found elicit antibodies at equivalent rates 
in both normal and cancer patients. These antibodies can be considered as part of the normal 
repertoire of na-Ab. Those antigens eliciting antibodies at higher frequencies in RCC patients 
may reflect the metabolic changes induced by the presence of the tumor. Therefore, this study 
has identified a portion of the ‘Immunculus’, some of which are indicators of cancer. 
 
With regard to the RCC immunome, a total of 26 antigens were identified that react solely 
with RCC sera. They may also react with other cancer sera but this has yet to be tested. 
Sixteen of the antibodies were found in only 1 to 2 of the 35 patients. These may represent 
tumor specific antigens and are thus not suitable for inclusion in a panel of antibodies 
identifying RCC. Ten antibodies however were found in 11-23% of RCC patients and are 
suitable for such a diagnostic panel. As can be seen from Figure 12, up to 77% of RCC 
patients have antibodies to at least one of these antigens. Whether these autoantibodies are of 
prognostic remains to be seen. The three cancer/ testis antigens (TSGA10, PLU-1 and STK31) 
may also be of immunotherapeutic value. This will depend on the expression profile of these 
antigens in RCC. 
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Individual patient sera  
Clone 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 
HD-RCC-13 
MnSOD                                    
HD-TES-6 
SBP2                                    
HD-TES-9 
Chr.8 clone                                    
HD-TES-14 
TSGA10                                    
HD-TES-18 
VCIP                                    
HD-TES-27 
PLU-1                                    
HD-TES-30 
STK31                                    
Par-3ta 
                                   
se57-1 
                                   
HEXIM1 
                                   
 
Figure 12. Seroreactivity of the 35 RCC patients against the 10 antigens showing exclusive 
reactivity in RCC. 
Colored boxes represent positive seroreactivity. 
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5 Conclusions 
 
 
This work has contributed to the identification of RCC associated genes and the elucidation of 
the RCC immunome and the Immunculus. 
 
Through the use of SSH and Northern blotting a panel of genes has been identified which are 
significantly upregulated in high proportions of RCC patients. These genes are related to the 
main features of malignancy, i.e. growth dysregulation, angiogenesis and motility. These 
molecules may serve as diagnostic or therapeutic targets.  
 
The combination of SEREX and SADA has identified a total of 88 antigens which are 
reactive with RCC sera. The majority of these antigens (62) elicit antibodies also in healthy 
controls. These antibodies can be considered part of the natural antibody repertoire, 
disturbances to which may indicate disease. Of the remaining 26 antigens which do not elicit 
antibody responses in healthy controls, 10 may be used together as a panel of antigens 
identifying up to 77% of RCC. These antigens/ antibodies may also serve as diagnostic, 
prognostic or therapeutic markers.  
 
Remaining questions are 1) the immunogenicity of these antigens in other cancers, 2) 
expression profile of the cancer/ testis antigens in RCC and 3) the full cloning and 
identification of the unknown antigens. 
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List of Abbreviations 
 
Weights and measures: 
 
bp  base pairs 
Ci  Curie 
G  gram 
hrs  hours 
kb  kilobases 
kD  kilodalton 
l  liter 
M  Molar 
mg  milligram 
min.  minutes 
ml  milliliter 
mM  millimolar 
mg  microgram 
ng  nanogram 
sec.  seconds 
U  unit 
V  Volt 
0C  degrees Celsius 
 
 
Amino Acids: 
 
A  Alanine 
C  Cysteine 
D  Aspartic acid 
E  Glutamic acid 
F  Phenylalanine 
G  Glycine 
H  Histidine 
I  Isoleucine 
K  Leucine 
M  Methionine 
N  Asparagine 
P  Proline 
Q  Glutamine 
R  Arginine 
S  Serine 
T  Threonine 
V  Valine 
W  Tryptophan 
Y  Tyrosine 
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[a32P]dCTP  Deoxycytidine 5’-[ a  32P]-triphosphate, triethylammonium salt 
5-AZA-CdR  5-aza-2’-deoxycytidine 
5-FU   5-fluorouracil 
A   Adenine 
a.a   Amino acid 
Ab   Antibody 
ADCC   Antibody dependent cellular cytotoxicity 
AICD   Activation-induced cell death 
AJCC   American Joint Committee on Cancer 
AKAP9  A kinase anchor protein 9 
allo-SCT  allogenic stem cells 
AML   Acute Myeloid Leukemia 
AMV   Avian Myeloblastosis Virus 
AP   Alkaline Phosphatase 
AP1 or 2  Adaptor primer 1 or 2 
APC   Antigen presenting cell 
ARP   Angiopoietin-related protein 
ATP   Adenosine triphosphate 
ATX   Autotaxin 
BACE   Beta site amyloid precursor protein cleaving enzyme  
BCIP   5-bromo-4-chloro-3-indoyl phosphate p-toluidene salt 
BRDT   Bromodomain testis specific 
BSA   Bovine serum albumin 
C   Cytosine 
C1-RC  C1 respiratory complex 
CA   Carbonic anhydrase 
CD   Cluster of differentiation 
CDA1   Cell division autoantigen 1 
cDNA   Complementary DNA 
CENP   Centromere protein 
CIAP   Calf Intestinal alkaline Phosphatase 
CKAP2  Cytoskeleton associated protein 2 
CML   Chronic Myelogenous Leukemia 
CP   Ceruloplasmin 
cpm   Counts per minute 
CRA   13-cis retinoic acid 
CT   Cancer/ testis (antigen) 
cTAGE  CTCL tumor associated antigen 
CTCL   Cutaneous T-cell lymphoma 
CTL   Cytotoxic T lymphocyte 
dATP   2-Deoxyadenosine 5’ triphosphate 
DC   Dendritic cell 
dCTP   2-Deoxycytidine 5’ triphosphate 
DD RTPCR  Differential display RTPCR 
DEPC   Diethylpyrocarbonate 
dGTP   2-Deoxyguanosine 5’ triphosphate 
DMSO  Dimethylsulfoxide 
DNA   Deoxyribonucleic acid 
DNase   Desoxyribonuclease 
DNEL-2  Dynein heavy chain 
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dNTP   Desoxyribonucleoside triphosphate 
ds   Double strand 
DTT   Dithiothreitol 
dTTP   2-Deoxythymidinetriphosphate 
EBV   Epstein Barr Virus 
EDTA   Ethylenediaminetetraacetic acid 
EF   Elongation factor 
EGFR   Epidermal growth factor 
ELISA   Enzyme Linked Immunosorbent Assay 
EPAS   Endothelial PAS domain protein 
ER   Endoplasmic Reticulum 
EST   Expressed sequence tag 
et al.   And others (et aliqui) 
FACS   Flourescence-activted cell sorter 
FCS   Fetal calf serum 
FDA   Food and Drug Administration (USA) 
FGF-5   Fibroblast growth factor 5 
FITC   Flourescein-Iso-Thio-Cyanate 
G   Guanine 
GAPDH  Glycerinaldehydephosphate dehydrogenase 
GBP   Guanylate binding protein 
GMCSF  Granulocyte Macrophage Colony Stimulating Factor 
GOLGA4  Golgin subfamily a,4 
HCRC   Hereditary clear cell renal cell carcinoma 
HEXIM1  HMBA inducible transcript 1 
HIF   Hypoxia inducble factor 
HLA   Human Leukocyte Antigen 
HMBA  Hexamethylene-bis-acetamide 
HPRC   Hereditary papillary renal carcinoma 
HRO   Hereditary renal oncocytoma 
i.v.   Intravenous 
IFNa   Interferon alpha 
IFNb    Interferon beta 
IFNg   Interferon gamma 
Ig   Immunoglobulin 
IGFBP3  Insulin like growth factor binding protein 3 
IL-10   Interleukin 10 
IL-12   Interleukin 12 
IL-2   Interleukin 2 
IL-4   Interleukin 4 
IPTG   Isopropyl-b-D-thiogalactoside 
IRCC   Institute for Cancer Research and Treatment 
IRES   Internal ribosome entry site 
LAK   Lymphokine activated killer cells 
LB   Luria and Bertani culture medium 
LDH   Lactate dehydrogenase 
LO   Lysyl oxidase 
mAb   monoclonal antibody 
MAGE   Melanoma associated antigen 
MAPK  Mitogen-activated protein kinase 
MHC   Major Histocompatability Complex 
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MnSOD  Superoxide dismutase 2 
MOPS   3-(N-morpholino)propanesulfonic acid 
mRNA   Messenger RNA 
n.t.   Not tested 
na-Ab   Natural autoantibody 
NADH   Nicotinamide adenine dinucleotide 
NBT   p-nitroblue tetrazolium chloride 
NDCH   Nuclear distribution gene C homolog 
NF-? B   Nuclear factor ? B 
NK   Natural killer cells 
NMDA  N-methyl-D-aspartate 
NSS   Nephron sparing surgery 
OD   Optical density 
ORF   Open reading frame 
Par-3   Partitioning defective homolog 3 
PBL   Peripheral blood lymphocyte 
PBS   Phosphate buffered saline 
Pcdh   Protocadherin 
PCNA   Proliferating cell nuclear antigen 
PCR   Polymerase chain reaction 
PKA   Protein kinase A 
PKC   Protein kinase C 
PP1   Protein phosphatase type 1 
PRDX3  Peroxiredoxin 3 
PS1   Putative S1 RNA binding domain protein 
PSA   Prostate specific antigen 
PSMA7  Proteosome subunit, alpha type 7 
PTp   Protein Tyrosine phosphatase 
PX   Phox 
RACE   Rapid amplification of cDNA ends 
RAGE   RCC associated antigen 
RANBP2L1  RAN binding protein 2-like 1 
RAP140  Retinoblastoma-associated protein 140 
RB   Retinoblastoma protein 
RBBP   Retinoblastoma binding protein 
RCC   Renal Cell Carcinoma 
rhIFNg   Recombinant human IFNg 
RNA   Ribonucleic acid 
RNase   Ribonuclease 
RPHPLC  Reverse phase high performance liquid chromatography 
rpm   Revolutions per minute 
RTPCR  Reverse transcriptase polymerase chain reaction 
SADA   Serum antibody detection array 
SART3  Squamous cell carcinoma antigen recognized by T cells 3 
SBNO1  Strawberry notch homolog-1 
SCID   Severe combined immunodeficiency 
SCP-1   Synaptonemal complex protein 1 
SDS   Sodium Dodecylsulfate 
SemG   SemaphorinG 
SEREX  Serological analysis of recombinant cDNA expression libraries 
SERPA  Serological proteome analysis 
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SNX6   Sorting nexin 6 
Sp3b   Splicing factor 3b 
SPEAR  Serological and proteomic evaluation of antibody responses 
ss   Single strand 
SSC   Sodium saline citrate 
SSc   Systemic sclerosis 
SSH   Suppression subtractive hybridization 
STK   Serine threonine kinase  
SUPT5H  Suppressor of Ty 
T   Thymidine 
TAE   Tris-Acetate-EDTA 
TBST   Tris buffered saline with 0.5% Tween 
Tc   T cytotoxic cell 
Th   T helper cells 
TILs   Tumor infiltrating Lymphocytes 
TNM   Tumor, node, metastases (staging system) 
Tris   Tris[hydroxymethyl]aminomethane 
UACA   Uveal autoantigen 
UBD   Diubiquitin 
UICC   Union Internationale Contre le Cancer 
UV   Ultraviolet 
VCIP   Valosin containing protein 
VEGF   Vascular endothelial growth factor 
VHL   von Hippel Lindau disease 
VLB   Vinblastine 
VSMC   Vascular smooth muscle cells 
WBS   William-Beuren syndrome 
X-gal   5-bromo-4-chloro-3-indolyl bd-galactopyrano-side 
ZNF   Zinc finger protein 
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